

PUBLICATIONS EAP CB (SITUATION SEPTEMBER 2020)

Original papers published in peer reviewed journals

1. Rios-Leyvraz M, Bochud M, Tabin R, Genin B, Russo M, **Eap CB**, Bovet P, Chiolero A. Monitoring caffeine intake in children with a questionnaire and urine collection: a cross-sectional study in a convenience sample in Switzerland. *European Journal of Nutrition* (in press)
2. Weisskopf E, Guidi M, Fischer CJ, Bickle Graz M, Beaufils E, Nguyen KA, Morisod Harari M, Rouiller S, Rothenburger S, Gaucherand P, Kassai-Koupai B, Borradori Tolsa C, Epiney M, Tolsa JF, Vial Y, Hascoët JM, Claris O, **Eap CB**, Panchaud A, Csajka C. A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: prediction of infant drug exposure through breast milk. *Br J Clin Pharmacol* 2020;86:1642-1653
3. Glatard A, Guidi M, Delacrétaz A, Dubath C, Grosu C, Laaboub N, von Gunten A, Conus P, Csajka C*, **Eap CB*** Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin concentrations and Body Weight Gain by Pharmacokinetic-Pharmacodynamic Analyses. *Joint corresponding author. *Clin Pharmacokinet.* 2020 Mar;59(3):371-382. **Facteur d'impact 4.7 (2018)**
4. Dubath C, Delacrétaz A, Glatard A, Vollenweider P, Preisig M, Richard-Lepouriel H, Hasler R, Gamma F, Solida A, Thonney J, Fassassi S, von Gunten A, Conus P, **Eap CB**. Evaluation of cardiometabolic risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. *J Clin Psychiatry* 81:3 May/June 2020
5. Baumann P, **Eap CB**, Gastpar M. The effect of perazine on the CYP2D6- and CYP2C19-phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients. *Basic & Clinical Pharmacology & Toxicology* 2020; 126:444-447
6. Kandors S, Pisanu C, Bandstein M, Jonsson J, Castela E, Pisits G, Gholam-Rezaee M, **Eap CB**, Preisig M, Schiöth HB, Mwinyi J. A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. *Drug Development Research* 2020 Feb;81(1):102-113. **Facteur d'impact 1.7 (2018)**
7. Rochat C, **Eap CB**, Bochud M, Chatelan A. Caffeine consumption in Switzerland: results from the first national nutrition survey menuCH. *Nutrients* 2019 Dec 20;12(1). pii: E28 **Facteur d'impact 4.2 (2018)**
8. Delacrétaz A, Glatard A, Dubath C, Gholam-Rezaee M, Sanchez-Mut JV, Gräff J, von Gunten A, Conus P, **Eap CB**, Psychotropic drug-induced genetic-epigenetic modulation of CRT1 gene is associated with early weight gain in a prospective study of psychiatric patients. *Clinical Epigenetics* 2019;11:198. **Facteur d'impact 5.5 (2018)**
9. Ansermot N, Bochatay M, Schläpfer J, Gholam M, Gonthier A, Conus P, **Eap CB**. Prevalence of ECG abnormalities and risk factors for QTc interval prolongation in hospitalized psychiatric patients. *Therapeutic Advances in Psychopharmacology* 2019, Vol 9: 1-13 DOI: 10.1177/ 2045125319891386. **Facteur d'impact 3.0 (2018)**
10. Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, Marzolini C, **Eap CB**, Decosterd LA, Csajka C and the Swiss HIV Cohort Study. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. *Br J Clin Pharmacol.* 2019;85(9):2022-2032. **Facteur d'impact 3.9 (2018)**.
11. Glatard A, Guidi M, Dobrinas M, Cornuz J, Csajka C* and **Eap CB***. Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population. * Equal contribution. *Eur J Clin Pharmacol* 2019; 75(7):939-949. **Facteur d'impact 2.8 (2018)**
12. Delacrétaz A, Vandenberghe F, Glatard A, Dubath C, Levier A, Gholam-Rezaee M, Holzer L, Ambresin A-E, Conus P, **Eap CB**. Lipid disturbances in adolescent treated with second-generation antipsychotics: Clinical determinants of plasma lipid worsening and new-onset hypercholesterolemia. *J Clin Psychiatry* 80:3, May/June 2019. **Facteur d'impact 4.0 (2018)**
13. Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S and WFSBP Guideline Task Force Chairs. WFSBP Guideline Task Force Chairs: Michael Bauer, Michael Berk, Marijana Bras, Philippe Courtet, Bruno Dubois, **CB Eap**, Wolfgang Gaebel, Angelos Halaris, Siegfried Kasper, Nick Kates, Walter Kaye, Sidney Kennedy, Henry R. Kranzler, Rupert Lanzenberger, Jeffrey Lieberman, Joel Paris, Georgios Petrides, Dan Rujescu, Thomas Schläpfer, Andrea Schmit, Leo She, Constantin Soldato, Nikos Stefanis, Florence Thibaut, Tanelki Tolga, Josef Zohar. WFSBP guidelines on how to grade evidence of psychiatric and psychosocial treatments. *World J Biol Psychiatry* 2019; Jan 20(1):2-16. **Facteur d'impact 4.0 (2018)**.
14. Saigi-Morgui N, Quteineh L, Bochud PY, Crettol S, Kutalik Z, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccacal PM, Pascual M, **Eap CB** and the Swiss Transplant Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation. *The Pharmacogenomics Journal* 2019; 19:53-64. **Facteur d'impact 3.5 (2018)**.

15. Quteineh L, Agnieszka W, Bochud PY, Crettol S, Vandenberghe F, Venetz JP, Manuel O, Golshayan D, Lehmann R, Mueller NJ, Binet I, van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccacal PM, Kutalik Z, Marques-Vidal P, Vollenweider P, Recher M, Hess C, von Gunten A, Conus P, Pascual MI, **Eap CB**, on behalf of the Swiss Transplant Cohort Study. Genetic immune and inflammatory markers associated with diabetes in solid organ transplant recipients. *Am J Transplant* 2019;19:238-246. **Facteur d'impact 7.2 (2018)**.
16. Delacrétaz A, Vandenberghe F, Glatard A, Levier A, Dubath C, Ansermot N, Crettol-Wavre S, Gholam-Rezaee M, Guessous I, Bochud M, von Gunten, M, Conus P, **Eap CB**, Association between plasma caffeine and other methylxanthines and metabolic parameters in a psychiatric population treated with psychotropic drugs inducing metabolic disturbances. *Frontiers in Psychiatry* Nov. 2018; 9:573. **Facteur d'impact 3.2 (2018)**.
17. Ponte B, Pruijm M, Ackermann D, Ehret G, Ansermot N, Staessen J, Vogt B, Pechère-Bertschi A, Burnier M, Martin PY, **Eap CB** Bochud M, Guessous I. Associations of urinary caffeine and caffeine metabolites with arterial stiffness in a large population-based study. *Mayo Clin Proc* 2018; 93(3):586-596. **Facteur d'impact 7.1 (2018)**.
18. Weisstanner C, Kägi G, Krammer W, **Eap CB**, Wiest R, Missimer JH, Weder BJ. The effect of a single dose of escitalopram on sensorimotor networks. *Brain and Behavior* 2018; 8(6) e00975. **Facteur d'impact 2.1 (2018)**.
19. Vandenberghe F*, Najar-Giroud A*, Holzer L, Conus P, **Eap CB***, Ambresin A-E*. Second-generation antipsychotics in adolescent psychiatric patients: metabolic effects and impact of an early weight change to predict longer term weight gain. *Journal of Child and Adolescent Psychopharmacology* 2018; 28(4):258-265. **Facteur d'impact 2.2 (2018)**. *equal contribution.
20. Ansermot N *, Jordanov V *, Smogur M, Holzer L, **Eap CB**. Psychotropic drug prescription in adolescents: a retrospective study in a Swiss psychiatric university hospital. *Journal of Child and Adolescent Psychopharmacology* 2018;(3):192-204. **Facteur d'impact 2.2 (2018)**. *equal contribution.
21. Conus P, Fournier M, Xin L, Baumann PS, Ferrari C; Cousins A, Alameda L, Gholam-Rezaee M, Golay P, Jenni R, Wilson Woo T-U, Keshavan MS, **Eap CB**, Wojcik J, Cuenod M, Buclin T, Gruetter R, Seidman LJ, Do KQ. N-Acetyl-Cysteine in a double blind randomized placebo controlled trial: towards biomarker guided treatment in early psychosis. *Schizophrenia Bulletin* 2018; 44(2):317-327. **Facteur d'impact 7.3 (2018)**.
22. Delacrétaz A, Vandenberghe F, Gholam-Rezaee M, Saigi Morgui N, Glatard A, Thonney J, Solida-Tozzi A, Kolly S, Fassassi Gallo S, Baumann P, Zulauff Vallotton S, Berney S, Hasler R, Aubry J-M, Ebbing K, von Gunten A, Conus P, **Eap CB**. Early changes of blood lipid levels during psychotropic drug treatment as predictors of long-term lipid changes and of new onset dyslipidemia. *Journal of Clinical Lipidology* 2018; 12(1):219-229. **Facteur d'impact 3.0 (2018)**.
23. Rossetti C, Sciarra D, Petit J-M, **Eap CB**, Halfon O, Magistretti PJ, Boutrel B and Cardinaux JR. Gender-specific alteration of energy balance and circadian locomotor activity in the *Crtc1* knockout mouse model of depression. *Translational Psychiatry* 2017 Dec 8; 7(12):1269. **Facteur d'impact 4.7 (2017)**.
24. Delacrétaz A, Santos Lagares P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, **Eap CB**. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. *Pharmacogenetics & Genomics* 2017, 27:464-472. **Facteur d'impact 2.3 (2017)**.
25. Forni Ogna V, Bassi I, Menetrey I, Muller O, Tousset E, Fontana P, Eeckhout E, **Eap CB**, Vrijens B, Burnier M and Wuerzner G. Comparative long-term effect of three anti-P2Y12 drugs after percutaneous angioplasty: an observational study based on electronic drug adherence monitoring. *Frontiers in Pharmacology* 8:article 738, 2017. **Facteur d'impact 3.8 (2017)**.
26. Glatard A, Dobrinas M, Gholam-Rezaee M, Lubomirov R, Cornuz J, Csajka C, **Eap CB**. Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy. *Experimental and Clinical Psychopharmacology* 2017; 25(5):353-362. **Facteur d'impact 2.4 (2017)**.
27. Delacrétaz A*, Zdravovic A*, Vandenberghe F, Saigi Morgui N, Glatard A, Quteineh L, Gholam-Rezaee M, Raffoul W, Laurent-Applegate LA, Jafari P, Gamma F, von Gunten A, Conus P, **Eap CB**. Association of variants of *SH2B1* and of *RABEP1* with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs. *Gene* 2017; 628:8-15. **Facteur d'impact 2.5 (2017)** * Equal contribution
28. Sikhayeva NS, Iskakova AA, Saigi-Morgui N, Zholdybaeva EV, Momynaliev KT, **Eap CB**, Ramankulov EM. Association of 28 single nucleotide polymorphisms in type 2 diabetes mellitus in the Kazakh population. *BMC Medical Genetics* 2017:18:76. **Facteur d'impact 1.9 (2017)**.
29. Weisskopf E, Panchaud A, Fischer CJ, Bickle Graz M, Morisod Harari M, Beaufils E, Nguyen KA, Gaucherand P, Grosjean D, Rothenburger S, Tolsa J-F, Borradori Tolsa C, Epiney M, Vial Y, Hascoët J-M, Claris O, Csajka C, **Eap CB**, and Ansermot N. Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-

electrospray mass spectrometry. *J Chrom B* 2017; 1057:101-109 DOI: 10.1016/j.jchromb.2017.04.039. **Facteur d'impact 2.4 (2017).**

30. Quteineh L, Bochud PY, Golshayan D, Crettol S, Venetz JP, Manuel O, Kutalik Z, Treyer A, Lehmann R, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Gasche-Soccal P, Pascual M, **Eap CB** and the Swiss Transplant Cohort Study. *CRTC2* polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation. *The Pharmacogenomics Journal* 2017 Jan; 17(1):69-75. **Facteur d'impact 3.8 (2017).**
31. Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, Artati A, **Eap CB**, Ehret G, Friedrich N, Ganna A, Guessous I, Homouth G, Lind L, Magnusson PK, Mangino M, Pedersen NL, Pietzner M, Suhre K, Völzke H, Bochud M, Spector TD, Grabe HJ, Ingelsson E. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. *Human molecular Genetics* 2016; 25(4):5472-5482. **Facteur d'impact 5.3 (2016).**
32. Petrovic D, Estoppey Younes S, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Mohaupt M, Paccaud F, Vogt B, Pechère-Bertschi A, Martin P-Y, Burnier M, **Eap CB**, Bochud M, Guessous I. Relation of 24-hour urinary caffeine and caffeine metabolite excretions with self-reported consumption of coffee and other caffeinated beverages in the general population. *Nutrition and Metabolism* (2016) 13:81 Doi 10.1186/s12986-016-0144-4. **Facteur d'impact 3.0 (2016).**
33. Forni Ogna V, Menetrey I, Muller O, Tousset E, Guihard L, Fontana P, Eeckout E, **Eap CB**, Vrijens B, Burnier M, Wuerzner G. Effect of long-term adherence to clopidogrel on the VASP-PRI after elective coronary stent implantation: a randomized controlled study. *Br J Clin Pharmacol* 2016 Dec; 82(6):1486-1497. **Facteur d'impact 3.5 (2016).**
34. Csajka C, Crettol S, Guidi M, **Eap CB**. Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid Dependent Patients. *Clin Pharmacokinet* 2016; 55:1521-1533. **Facteur d'impact 5.2 (2016).**
35. Vandenberghe F, Saigi Morgui N, Delacrétaz A, Quteineh L, Crettol S, Ansermot N, Gholam-Rezaee M, von Gunten A, Conus P, **Eap CB**. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. *Pharmacogenetics & Genomics* 2016, 26:547-557. **Facteur d'impact 2.2 (2016).**
36. Saigi-Morgui N, Quteineh L, Bochud PY, Crettol S, Kutalik Z, Wojtowicz A, Bibert S, Beckmann S, Mueller NJ, Binet I, van Delden C, Steiger J, Mohacsi P, Stirnimann G, Soccal PM, Pascual M, **Eap CB** and the Swiss Transplant Cohort Study. Weighted genetic risk scores and prediction of weight gain in Solid Organ Transplant populations. *Plos One* 11(10):e014443, 2016. **Facteur d'impact 2.8 (2016).**
37. Weisskopf E, Panchaud A, Nguyen K A, Hascoët J-M, Csajka C, **Eap CB**, Ansermot N, and the collaborators of the SSRI-Milk study. Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry. *Journal Pharmaceutical Biomedical Analysis* 2016; 131:233-245. **Facteur d'impact 3.3 (2016).**
38. Quteineh L, Preisig M, Rivera M, Milaneschi Y, Castelao E, Gholam-Rezaee M, Vandenberghe F, Saigi-Morgui N, Delacrétaz A, Cardinaux JR, Willemsen G, Boomsma D I, B WJH Penninx, Ching-López A, Conus P, **Eap CB**. Association of *CRTC1* polymorphisms with obesity markers in subjects from the general population with lifetime depression. *Journal of Affective Disorders* 198 (2016) 43–49. **Facteur d'impact 3.4 (2016).**
39. Saigi-Morgui N, Vandenberghe F, Delacrétaz A, Quteineh L, Gholam-Rezaee M, Aubry JM, von Gunten A, Kutalik Z, Conus P, **Eap CB**. Association of Genetic Risk Scores (GRS) with Body Mass Index in Swiss psychiatric cohorts. *Pharmacogenetics and Genomics* 2016 May; 26(5):208-217. **Facteur d'impact 2.2 (2016).**
40. Marie-Claire C, Crettol S, Cagnard N, Bloch V, Mouly S, Laplanche J-L, Bellivier F, Lépine JP, **Eap CB**, Vorspan F. Variability of response to methadone: genome-wide DNA methylation analysis in two independent cohorts. *Epigenomics* 2016;8(2):181-195. **Facteur d'impact 4.5 (2016).**
41. Liu Y, Jann M, Vandenberg C, **Eap CB**, Shamsia SA. Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellarelectrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug–drug interaction. *J Chrom A* 1420:119-128, 2015. **Facteur d'impact 3.9 (2015).**
42. Sakae DY, Marti F, Lecca S, Vorspan F, Martín-García E, Morel LJ, Henrion A, Gutiérrez-Cuesta J, Besnard A, Heck N, Herzog E, Bolte S, Prado VF, Prado MAM, Bellivier F, **Eap CB**, Crettol S, Vanhoutte P, Caboche J, Gratton A, Moquin L, Giros B, Maldonado R, Daumas S, Mamelí M, Jamain S, El Mestikawy S. The absence of *VGLUT3* predisposes to cocaine abuse by increasing dopamine and glutamate signaling in the nucleus accumbens. *Molecular Psychiatry* 2015 Nov;20(11):1448–1459. **Facteur impact 13.3 (2015).**

43. Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, **Eap CB**. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. *Clinical Pharmacokinetics* 2015; 54:1259–1272. **Facteur impact 4.8(2015)**.
44. Saigi Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Choong E, Gholam-Rezaee M, Magistretti P, Aubry J-M, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Kutalik Z, Conus P, **Eap CB**. Association of PCK1 with body mass index and other metabolic features in patients with psychotropic treatments. *J Clin Psychopharmacol* 2015 Oct;35(5):544-52. **Facteur d'impact 3.0 (2015)**.
45. Delacrétaç A, Preisig M, Vandenberghe F, Saigi Morgui N, Quteineh L, Choong E, Gholam-Rezaee M, Kutalik Z, Magistretti P, Aubry JM, von Gunten A, Castelao E, Vollenweider P, Waeber G, Conus P, **Eap CB**, Influence of *MCHR2* and *MCHR2-AS1* genetic polymorphisms on body mass index in psychiatric patients and in subjects from the general population with present or past atypical depression. *Plos One* 2015 October 13 ; 10(10) :e0139155. **Facteur d'impact 3.1 (2015)**.
46. Vandenberghe F, Gholam Rezaee M, Saigi Morgui N, Delacrétaç A, Choong E, Solida A, Kolly S, Thonney J, Fassassi S, Ahmed H, von Gunten A, Conus P, **Eap CB**. Importance of early weight gain changes to predict long term weight gain during psychotropic drug treatment. *J Clin Psychiatry* 2015(76):11:e1417-e1423. **Facteur d'impact 5.4 (2015)**.
47. Quteineh L, Vandenberghe F, Saigi Morgui N, Delacretaz A, Choong E, Gholam-Rezaee M, Magistretti P, Bondolfi G, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Bochud M, Kutalik Z, Conus P, **Eap CB**. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. *Pharmacogenetics & Genomics* 2015, 25(5):246-258. **Facteur d'impact 2.9 (2015)**.
48. Guessous I, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Vuistiner P, Staessen JA, Gu Y-M, Paccaud F, Mohaupt MG, Vogt B, Pechere-Berstchi A, Martin PY, Burnier M, **Eap CB**, Bochud M. Associations of ambulatory blood pressure with urinary caffeine and caffeine metabolites excretions. *Hypertension* 2015;65:691-696. **Facteur d'impact 6.4 (2015)**.
49. Diaz FJ, **Eap CB**, Ansermot N, Crettol S, Spina E, de Leon J. Can valproic acid be an inducer of clozapine metabolism? *Pharmacopsychiatry* 2014;47:89-96. **Facteur d'impact 1.9 (2014)**.
50. Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Stancu I, Alnawaqil A-M, Bula C, Zumbach S, Gaillard M, Giannakopoulos P, Von Gunten A, Csajka C, **Eap CB**. Population pharmacokinetic approach to evaluate the effect of *CYP2D6*, *CYP3A*, *ABCB1*, *POR* and *NR1I2* genotypes on donepezil clearance **Br J Clin Pharmacol** 2014; 78(1):135-144. **Facteur d'impact 3.9 (2014)**.
51. Gradinaru J, Vullioud A, **Eap CB**, Ansermot N. Quantification of typical antipsychotics in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring *Journal of Pharmaceutical and Biomedical Analysis* 2014; 88:36-44. **Facteur d'impact 3.0 (2014)**.
52. Holzer L, Pihet S, Moses Passini C, Feijo I, Camus D, **Eap CB**. Substance use in adolescent psychiatric outpatients: self-report, healthcare providers's clinical impressions and urine screening *J of Child and Adolescent substance abuse* (2014) 23:1-8. **Facteur d'impact 0.6 (2014)**.
53. Khazaal Y, Preisig M, Chatton A, Kaufmann N, Bilancioni R, **Eap CB**. Use of high doses of quetiapine in bipolar disorder episodes are not linked to high activity of cytochrome P4503A4 and/or cytochrome P4502D6. *Psychiatric Quaterly* (2013) 84: 329-335. **Facteur d'impact 1.3 (2013)**.
54. Ansermot N, Brawand Amey M, Kottelat A, **Eap CB**. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra high pressure liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. *J Chrom A* 2013; 1292:160–172. **Facteur d'impact 4.3 (2013)**.
55. Noetzli M, Guidi M, Ebbing K, Eyer S, Zumbach S, Giannakopoulos P, von Gunten A, Csajka C, **Eap CB**. Relationship of *CYP2D6*, *CYP3A*, *POR* and *ABCB1* genotypes with galantamine plasma concentrations. *Therapeutic Drug Monitoring* 2013; 35:270-275. **Facteur d'impact 1.9 (2013)**.
56. Dobrinas M, Cornuz J, **Eap CB**. Pharmacogenetics of *CYP1A2* activity and inducibility in smokers and exsmokers. *Pharmacogenetics & Genomics* 2013, 23:286-292. **Facteur d'impact 3.5 (2013)**.
57. Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, Thomazic V, Alnawaqil AM, Maurer S, Zumbach S, Giannakopoulos P, von Gunten A, Csajka C, **Eap CB**. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. *Clinical Pharmacokinetics* 2013; 52:211-223. **Facteur d'impact 5.5 (2013)**.
58. Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, **Eap CB**. Contribution of *CYP2B6* alleles to explain extreme (S)-methadone plasma levels: a *CYP2B6* gene sequencing study. *Pharmacogenetics & Genomics* 2013, 23:84–93. **Facteur d'impact 3.5 (2013)**.
59. Choong E, Quteineh L, Cardinaux J-R, Gholam-Rezaee M, Vandenberghe F, Dobrinas M, Bondolfi G, Etter M, Holzer L, Magistretti P, Von Gunten A, Preisig M, Vollenweider P, the GIANT Consortium, the ODEX team, Beckmann JS, Pralong FP, Waeber G, Kutalik Z, Conus P, Bochud M, **Eap CB**. Influence of *CRTC1* polymorphisms on body mass index and fat mass in psychiatric patients and in the general

- adult population. *JAMA Psychiatry* 2013; 70(10):1011-1019 (old name: Archives of General Psychiatry) doi:10.1001/jamapsychiatry.2013.187.
60. Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot E, Giacometti Bickel G, Bondolfi G, Conus P, **Eap CB**. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and Pregnane X receptor on risperidone exposure and drug-induced side-effects. *J Clin Psychopharmacol* 2013; 33: 289-298. **Facteur d'impact 3.8 (2013)**.
 61. Haouala A, Widmer N, Montermurro M, Leyvraz S, Buclin T, **Eap CB**, Decosterd LA, Csajka C. Prediction of free imatinib concentrations based on total plasma levels in gist patients. *Br J Clin Pharmacol* 75:4; 1007-18 (2013). **Facteur d'impact 3.7 (2013)**.
 62. Lüthi G, Blangy V, **Eap CB**, Ansermot N. Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high-pressure liquid chromatography tandem mass spectrometry. *Journal of Pharmaceutical and Biomedical Analysis* 77 (2013) 1– 8. **Facteur d'impact 2.8 (2013)**.
 63. Fayet Mello A, Buclin T, Guignard N, Cruchon S, Cavassini M, Grawe C, Gremlich E, Aebi Popp K, Schmid F, **Eap CB**, Telenti A, Biollaz J, Decosterd A L, Martinez de Tejada B. Free and total plasma concentrations of lopinavir, atazanavir, and nevirapine during pregnancy, at delivery and post-partum. *Antiviral therapy* 2013; 18(2):171-182. **Facteur d'impact 3.1 (2013)**.
 64. Noetzli M, Ansermot N, Dobrinas M, **Eap CB**. Simultaneous determination of antimentia drugs in human plasma: procedure transfer from HPLC-MS to UPLC-MS/MS. *J Pharmaceutical Biomedical Analysis* 64-65:16-25, 2012. **Facteur d'impact 2.9 (2012)**.
 65. Ansermot N, Brawand Amey M, **Eap CB**, Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. *J Chrom B* 885– 886 (2012) 117– 130. **Facteur d'impact 2.5 (2012)**.
 66. Jaquenoud Sirot E, Harenberg S, Vandel P, Mendonça Lima C A, Perrenoud P, Kemmerling K, Zullino DF, Hilleret H, Crettol S, Jonzier-Perey M, Powell Golay K, Brocard M, **Eap CB**, Baumann P. Multicenter study on the clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression. *J Clin Psychopharmacol*, 32, 622-29 (2012). **Facteur d'impact 3.5 (2012)**.
 67. Loayza N, Crettol S, Riquier F, **Eap CB**. Adherence to antidepressant treatment: what the doctor thinks and what the patient says. *Pharmacopsychiatry* 45: 204–207, 2012. **Facteur d'impact 2.1 (2012)**.
 68. Guessous I, Dobrinas M, Kutalik Z, Pruijm M, Ehret G, Maillard M, Bergmann S, Beckmann JS, Cusi D, Rizzi F, Cappucio F, Cornuz J, Paccaud F, Mooser V, Gaspoz JM, Waeber G, Burnier M, Vollenweider P, **Eap CB**, Bochud M. Caffeine intake, and CYP1A2 variants associated with high caffeine intake, protect non-smokers from hypertension. *Human Molecular Genetics* 21(14):3283-3292, 2012. **Facteur d'impact 7.7 (2012)**.
 69. Dobrinas M, Cornuz J, Pedrido L, **Eap CB**. Influence of cytochrome P450 oxidoreductase (POR) genetic polymorphisms on CYP1A2 activity and inducibility by smoking. *Pharmacogenetics & Genomics* 22(2):143-151, 2012. **Facteur d'impact 3.6 (2012)**.
 70. Choong E, Bondolfi G, Etter M, Jermann F, Aubry JM, Bartolomei J, Gholam-Rezaee M, **Eap CB**. Psychotropic drug induced weight gain and other metabolic complications in a Swiss Psychiatric population. *J Psychiatric Research* 46:540-548, 2012. **Facteur d'impact 4.0 (2012)**.
 71. Dobrinas M, Choong E, Noetzli M, Cornuz J, Ansermot N, **Eap CB**. Quantification of nicotine, cotinine, trans-3'-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC-tandem mass spectrometry for a clinical study on smoking cessation. *J Chrom B* 879: 3574-82, 2011. **Facteur d'impact 2.9 (2011)**.
 72. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, **Eap CB**. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity. *Clin Pharmacol Ther* 90(1) :117-125, 2011. **Facteur d'impact 6.0 (2011)**.
 73. Noetzli M, Choong E, Ansermot N, **Eap CB**. Simultaneous determination of antimentia drugs in human plasma for therapeutic drug monitoring. *Therapeutic Drug Monitoring* 33(2): 227-38, 2011. **Facteur d'impact 2.5 (2011)**.
 74. Choong E, Rudaz S, Kottelat A, Haldemann S, Guilleme D, Veuthey JL, **Eap CB**. Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring. *J Chrom B* 879: 1544-50, 2011. **Facteur d'impact 2.9 (2011)**.
 75. Pelet A, Favrat B, Cavassini M, **Eap CB**, Besson J, Monnat M. Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. *Am J Drug Alcohol Abuse* 37:264-8, 2011.
 76. Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hämmig R, Monnat M, Preisig M, **Eap CB**. β -arrestin2 influences the response to methadone in opioid dependent patients. *The Pharmacogenomics Journal* 11:258-266, 2011. **Facteur d'impact 4.5 (2011)**.
 77. Nikisch G, Baumann P, Oneda B, Kessler B, Weisser H, Mathé AA, Takashi Y, Kehr J, Wiedemann G, **Eap CB**. Cytochrome P450 and ABCB1 genetics: Association with quetiapine and norquetiapine

- plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. *J Psychopharmacol* 25(7):896-907, 2011. **Facteur d'impact 3.0 (2011).**
78. Ansermot N, Albayrak Ö, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Déglon JJ, Faouzi M, Scherbaum N, **Eap CB**. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. *Archives of Internal Medicine* 170(6): 529-36 Mar 22; 2010. **Facteur d'impact 10.6 (2010).**
 79. Samer CF; Daali Y; Wagner M; Hopfgartner G; **Eap CB**; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. *Br J Pharmacol* 160: 907-18, 2010. **Facteur d'impact 3.1 (2010).**
 80. Samer CF; Daali Y; Wagner M; Hopfgartner G; **Eap CB**; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA. Genetic polymorphism and drug interactions modulating CYP2D6 and CYP3A activities have a major impact on oxycodone analgesic efficacy and safety. *Br J Pharmacol* 160: 919-30, 2010. **Facteur d'impact 3.1 (2010).**
 81. Choong E, Rudaz S, Kottelat A, Guilleme D, Veuthey JL, **Eap CB**. Therapeutic drug monitoring of 7 psychotropic drugs and 4 metabolites in human plasma by HPLC-MS. *J Pharmaceut Biomed Analysis* 50: 1000-8 (2009). **Facteur d'impact 2.5 (2009).**
 82. Oneda B, Crettol S, Jaquenoud E, Bochud M, Ansermot N, **Eap CB**. The P450 oxidoreductase is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. *Pharmacogenetics and Genomics* 19:877-83, 2009 **Facteur d'impact 4.0 (2009).**
 83. Hallinan R, Crettol S, Agho K, Attia J, Besson J, Croquette-Krokar M, Hämmig R, Déglon JJ, Byrne A, Somogyi A, **Eap CB**. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. *Eur J Clin Pharmacol* 65:1113-1120 (2009). **Facteur d'impact 2.7 (2009).**
 84. Ansermot N, Rudaz S, Brawand-Amey M, Fleury-Souverain S, Veuthey JL, **Eap CB**. Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples. *J Chromatography B* 877:2301-2307 (2009). **Facteur d'impact 2.8 (2009).**
 85. Jaquenoud Sirot E, Knezevic B, Perla Morena G, Harenberg S, Oneda B, Crettol S, Ansermot N, Baumann P, **Eap CB**. ABCB1 and cytochromes P450 polymorphisms: clinical pharmacogenetics of clozapine. *J Clin Psychopharmacol* 29:319-26 (2009). **Facteur d'impact 5.1 (2009).**
 86. Arab-Alameddine M, Buclin T, Rotger M, Lubomirov R, Di Lulio J, Cavassini M, Fayet A, Decosterd LA, **Eap CB**, Biollaz J, Telenti A, Csajka C and the Swiss HIV Cohort Study. Population Pharmacokinetic and Pharmacogenetic Analysis of Efavirenz in HIV-1 Infected Individuals. *Clin Pharmacol Ther* 85:485-94 (2009). **Facteur d'impact 7.0 (2009).**
 87. Di Lulio J, Rotger M, Fayet A, Lubomirov R, Arab-Alameddine M, Cavassini M, Furrer HJ, Güntar HF, Colombo S, Csajka C, **Eap CB**, Decosterd LA, Telenti A. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenetics & Genomics* 19:300-9 (2009). **Facteur d'impact 4.0 (2009).**
 88. Nikisch G, **Eap CB**, Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: A pilot study *Pharmacological Research* 58:344-7, 2008. **Facteur d'impact 3.3 (2008).**
 89. Crettol S, Venetz JP, Fontana M, Aubert JD, Pascual M, **Eap CB**. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. *Ther Drug Monitor* 30(6):689-99 (2008). **Facteur d'impact 2.4 (2008).**
 90. Daghli MRC, Williams TM, Wilson SJ, Taylor LG, **Eap CB**, Augsburger M, Giroud C, Brooks DJ, Myles JS, Grasby P, Lingford-Hughes AR, Nutt DJ. Brain dopamine response in human opioid addiction. *Br J Psychiatry* 193:65-72 (2008). **Facteur d'impact 5.1 (2008).**
 91. Zullino D, Krenz S, **Eap CB**, Bertolini M, Khan R. Over- and underreporting of recent drug use in subjects entering an inpatient detoxification unit. *Eur J Med Res* 13(1):15-20 (2008). **Facteur d'impact 1.0 (2008).**
 92. Fayet A, Beguin A, Martinez de Tejada B, Colombo S, Cavassini M, Gerber S, **Eap CB**, Telenti A, Buclin T, Biollaz J, Decosterd LA. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in free fraction *Ther Drug Monitor* 30; 511-22, 2008. **Facteur d'impact 2.4 (2008).**
 93. Bochud M, **Eap CB**, Maillard M, Jonson T, Vollenweider P, Bovet P, Elston RC, Bergman S, Beckmann JS, Waterworth D, Moser V, Gabriel A, Burnier M. Associations of ABCB1 genetic variants with renal function in Africans and Caucasians. *BMC medical genomics* 1:21 (2008).
 94. Gex-Fabry M, **Eap CB**, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, Bertschy G. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. *Ther Drug Monitor* 30:474-82 (2008). **Facteur d'impact 2.4 (2008).**
 95. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, **Eap CB**. Influence of ABCB1 genetic polymorphism on cyclosporine intracellular concentrations in transplant recipients. *Pharmacogenetics & Genomics* 18:307-315, 2008. **Facteur d'impact 4.4 (2008).**

96. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Preisig M, **Eap CB**. Association of dopamine and opioid receptor gene polymorphisms with response to methadone during maintenance treatment. *Progress Neuro Psychopharmacol Biol Psy* 32:1722-27 (2008). **Facteur d'impact 2.6 (2008)**.
97. Saraeva RB, Paskaleva ID, Doncheva E, **Eap CB**, Ganev VS. Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements. *J Clin Pharm Ther* 32:641-9, 2007. **Facteur d'impact 1.4 (2007)**.
98. Crettol S, Digon P, Powell Golay K, Brawand-Amey M, **Eap CB**. In vitro P-glycoprotein-mediated transport of (R)- and (S)-methadone, LAAM and their main metabolites. *Pharmacology* 80:304-311, 2007. **Facteur d'impact 1.2 (2007)**.
99. Sporkert F, Augsburger MP, Giroud C, Brossard C, **Eap CB**, Mangin P. Determination and distribution of clotiapine (Entumine®) in human plasma, post-mortem blood and tissues samples from clotiapine-treated patients and from autopsy cases. *Forensic Science International* 170(2-3) 193-199, 2007. **Facteur d'impact 2.0 (2007)**.
100. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, **Eap CB**. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. *J Clin Psychopharmacol* 27(3):273-278, 2007. **Facteur d'impact 3.9 (2007)**.
101. Le Bloc'h Y, Baumann P, Stigler M, **Eap CB**, Zullino D. Efficacy and tolerability of quetiapine in Cluster B Personality Disorder : an open label study. *International Journal of Psychiatry in Clinical Practice* 11(2) 123-8, 2007. **Facteur d'impact 0.4 (2007)**.
102. **Eap CB**, Crettol S, Rougier JS, Schläpfer J, Correa-Sintra L, Déglon JJ, Besson J, Croquette-Krokar M, Abriel H. Stereoselective block of hERG channel and by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers *Clin Pharmacol Ther* 81:719-728, 2007. **Facteur d'impact 8.0 (2007)**.
103. Gex-Fabry M, Gervasoni N, Bondolfi G, Aubry JM, **Eap CB**, Bertschy G. Time course of response to paroxetine: influence of age, episode duration and plasma level. *Prog Neuro Psychopharmacol & Biol Psy* 31(4) 892-900, 2007. **Facteur d'impact 2.8 (2007)**.
104. **Eap CB**, Bochud M, Elston RC, Maillard M, Bovet P, Nussberger J, Schild L, Shamlaye C, Burnier M. The CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. *Hypertension* 49(5) 1007-1014, 2007. **Facteur d'impact 7.2 (2007)**.
105. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, **Eap CB**. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. *Clin Pharmacol Ther* 80(6) 668-81, 2006. **Facteur d'impact 8.1 (2006)**.
106. Colombo S, Buclin T, Décosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, **Eap CB**. Orosomucoid (Alpha 1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. *Clin Pharmacol Ther* 80(4) 307-18, 2006. **Facteur d'impact 8.1 (2006)**.
107. Widmer N, Decosterd LA, Csjaka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, **Eap CB**, Henry H, Biollaz J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha1-acid glycoprotein. *Br J Clin Pharmacol* 62(1) 97-112, 2006. Erratum *Br J Clin Pharmacol* DOI:10.1111/j.1365-2125.2010.03738.x. **Facteur d'impact 2.7 (2006)**.
108. Holzer L and **Eap CB**. Risperidone induced symptomatic hyperprolactinaemia in adolescents. *J Clin Psychopharmacol* 26(2) 167-171, 2006. **Facteur d'impact 4.6 (2006)**.
109. Bochud M, **Eap CB**, Elston RC, Bovet P, Maillard M, Schild L, Shamlaye C, Burnier M. Association of CYP3A5 genotypes with blood pressure and renal function in African families. *J Hypertension* 24(5) 923-929, 2006. **Facteur d'impact 4.0 (2006)**.
110. Bonsack C, Camus D, Kaufmann N, Spagnoli J, Aubert AC, Besson J, Baumann P, Borgeat F, Gillet M, **Eap CB**. Prevalence of drug use in a Swiss Psychiatric hospital: interview reports and urine screening. *Addictive Behaviors* 31(7) 1252-8, 2006. **Facteur d'impact 1.8 (2006)**.
111. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Gothuey I, Hämmig R, Monnat M, Hüttemann H, Baumann P, **Eap CB**. Methadone enantiomer plasma levels, CYP2B6, CYP2C9 and CYP2C19 genotypes, and response to treatment. *Clin Pharmacol Ther* 2005:78(6) 593-604. **Facteur d'impact 7.5 (2005)**.
112. de Medonça Lima C, Baumann P, Brawand-Amey M, Brogli C, Jacquet S, Cochard N, Powell Golay K, **Eap CB**. Effects of age and gender on citalopram and desmethylcitalopram steady-state plasma concentrations in adults and elderly depressed patients. *Progress in Neuro-Psychopharmacology & Biological Psychiatry* 29(6) 952-956, 2005. **Facteur d'impact 2.8 (2005)**.
113. Nikisch G, Mathé AA, Czernik A, Thiele J, Bohner J, **Eap CB**, Agren A, Baumann P. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with (S)-citalopram concentration in plasma and cerebrospinal fluid (CSF) and clinical response. *Psychopharmacology* 181(4) 751-60, 2005. **Facteur d'impact 4.0 (2005)**.

114. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, **Eap CB**. Increased clozapine plasma concentrations and side effects induced by smoking cessation in two CYP1A2 genotyped patients. *Ther Drug Monitor* 27(4) 539-543, 2005. **Facteur d'impact 2.7 (2005)**.
115. Chevalley AF, Besson J, Croquette-Krokar M, Davidson C, Dubois JA, Uehlinger C, **Eap CB**. Prevalence of the injection of methadone in three Swiss cities. *La Presse Médicale* 34(11) 776-80, 2005. **Facteur d'impact 0.4 (2005)**.
116. Fellay J, Marzolini C, Decosterd L, Powell Golay K, Baumann P, Buclin T, Telenti A, **Eap CB**. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. *Eur J Clin Pharmacol* 60(12) 865-73, 2005. **Facteur d'impact 2.3 (2005)**.
117. Nikisch G, Agren H, **Eap CB**, Czernik A, Baumann P, Mathé AA. Neuropeptide Y and corticotropin-releasing hormone in CSF marks response to antidepressive treatment with citalopram. *Int J Neuropsychopharmacol* 8:403-410, 2005. **Facteur d'impact 4.0 (2005)**.
118. Haller-Gloor F, **Eap CB**, Turgeon J, Baumann P. High-dose venlafaxine treatment in a depressed patient with a genetic CYP2D6 deficiency. *International J Psych Clin Pract* 8(3):191-195, 2004. **Facteur d'impact 0.3 (2004)**.
119. Giroud C, Katarzyna M, Sporkert F, **Eap CB**, Augsburger M, Cardinal P, Mangin P. A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography – mass spectrometry (HILIC-MS). *J Anal Toxicol* 28: 464-474, 2004. **Facteur d'impact 1.7 (2004)**.
120. Benmebarek M, Devaud C, Gex-Fabry M, Powell Golay K, Brogli C, Baumann P, Gravier B, **Eap CB**. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. *Clin Pharmacol Ther* 2004; 76(1): 55-63. **Facteur d'impact 6.8 (2004)**.
121. **Eap CB**, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Powell Golay K, Aubert AC, Baumann P, Telenti A, Kerb R. Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. *Eur J Clin Pharmacol* 60(4): 237-246, 2004. **Facteur d'impact 2.1 (2004)**.
122. **Eap CB**, Buclin T, Hustert E, Bleiber G, Powell Golay K, Aubert AC, Baumann P, Telenti A, Kerb R. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. *Eur J Clin Pharmacol* 60(4):231-236, 2004. **Facteur d'impact 2.1 (2004)**.
123. **Eap CB**, Bouchoux G, Powell Golay K, Baumann P. Determination of human plasma levels of levo-alpha-acetylmethadol (LAAM) and its metabolites by gas chromatography-mass spectrometry. *J Chromatogr B* 805(1):141-146, 2004. **Facteur d'impact 2.2 (2004)**.
124. Nikisch G, Mathé AA, Czernik A, **Eap CB**, Jiménez-Vasquez P, Brawand-Amey M, Baumann P. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid (CSF) of depressive patients: relationship with 5-HIAA in CSF and clinical response. *J Clin Psychopharmacol* 24(3): 283-290, 2004. **Facteur d'impact 4.4 (2004)**.
125. **Eap CB**, Fellay J, Buclin T, Bleiber G, Powell Golay K, Brocard M, Baumann P, Telenti A. CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. *Pharmacogenetics* 14(4):255-260, 2004. **Facteur d'impact 6.4 (2004)**.
126. Ciusani E, Zullino D, **Eap CB**, Brawand-Amey M, Broccard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients non-responding to venlafaxine: pharmacokinetic and clinical aspects. *Journal of Psychopharmacology* 18(4):559-66, 2004. **Facteur d'impact 2.3 (2004)**.
127. Paus E, Jonzier-Perey M, Cochard M, **Eap CB**, Baumann P. Chirality in the new generations of antidepressants: Stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine and 8-hydroxymirtazapine by LC-MS. *Ther Drug Monitor* 26:366-374, 2004. **Facteur d'impact 2.8 (2004)**.
128. Giroud C, Horisberger B, **Eap CB**, Augsburger M, Ménétrey A, Baumann P, Mangin P. Death following acute poisoning by moclobemide. *Forensic Sci Int* 140 (1):101-107, 2004. **Facteur d'impact 1.4 (2004)**.
129. **Eap CB**, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F. Non-response to clozapine and ultrarapid CYP1A2 activity clinical data and analysis of CYP1A2 gene. *J Clin Psychopharmacol* 24:214-219, 2004. **Facteur d'impact 4.4 (2004)**.
130. **Eap CB**, Bouchoux G, Powell Golay K, Baumann P. Determination of picogram levels of midazolam, and 1- and 4-hydroxymidazolam in human plasma by gas chromatography-negative chemical ionisation-mass spectrometry. *J Chromatogr B* 802(2):339-345, 2004. **Facteur d'impact 2.2 (2004)**.
131. Souverain S, **Eap CB**, Veuthey JL, Rudaz S. Automated LC-MS method for the fast stereoselective determination of methadone in plasma. *Clinical Chemistry and Laboratory medicine* 41(12):1615-1621, 2003. **Facteur d'impact 1.5 (2003)**.

132. Shinderman M, Maxwell S, Brawand-Amey M, Powell-Golay K, Baumann P, **Eap CB**. Cytochrome P4503A4 metabolic activity, methadone blood concentrations and methadone doses. *Drug and Alcohol Dependence* 69(2); 205-211, 2003. **Facteur d'impact 2.9 (2003)**.
133. Allorge D, Chevalier D, Lo-Guidice JM, Mrowinski M, Suard F, Baumann P, **Eap CB**, Broly F. Identification of a novel splice-site mutation in the CYP1A2 gene. *Br J Clin Pharmacol* 56(3); 341-344, 2003. **Facteur d'impact 2.5 (2003)**.
134. **Eap CB**, Felder C, Uehlinger C, Powell-Golay K. Increase of oral methadone dose in methadone injecting addict patients: a pilot study. *Journal of Addictive Diseases* 22(3): 7 – 17, 2003. **Facteur d'impact 1.7 (2003)**.
135. Frieboes RM, Sonntag A, Yassouridis A, **Eap CB**, Baumann P, Holsboer F, Steiger A. Clinical outcome after trimipramine in patients with delusional depression – a pilot study. *Pharmacopsychiatry* 36(1) 12 – 17, 2003. **Facteur d'impact 2.8 (2003)**.
136. Le Bloc'h Y, Woggon B, Weissenrieder H, Zullino D, Brawand-Amey M, Spagnoli J, **Eap CB**, Baumann P. Routine therapeutic drug monitoring in patients treated with 10 – 360 mg/day citalopram. *Therapeutic Drug Monitoring*, 25(5): 600-608, 2003. **Facteur d'impact 2.4 (2003)**.
137. **Eap CB**, Lessard E, Brawand-Amey M, Baumann P, Yessine MA, O'Hara G, Turgeon J. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. *Pharmacogenetics*, 13(1): 39-47, 2003. **Facteur d'impact 5.9 (2003)**.
138. Melichar JK, Myles JS, **Eap CB**, Nutt DJ. Using saccadic eye movements as objective measures of tolerance in methadone dependent individuals during the hydromorphone challenge test. *Addiction Biology*, 8(1) 59-66, 2003. **Facteur d'impact 1.3 (2003)**.
139. Begré S, von Bardeleben U, Ladewig D, Rochat S, Savary L, Powell K, Baumann P, **Eap CB**. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. *J Clin Psychopharmacol* 22(2) 211-215, 2002. **Facteur d'impact 4.2 (2002)**.
140. Steinacher L, Vandel P, Zullino DF, **Eap CB**, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetics and clinical pilot study. *European Neuropsychopharmacology* 12(3) 255-260, 2002. **Facteur d'impact 2.5 (2002)**.
141. Fellay J, Marzolini C, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Meaden ER, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, **Eap CB**, Telenti A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *The Lancet* 359(9600) 30 – 36, 2002. **Facteur d'impact 15.4 (2002)**.
142. Wikell C, **Eap CB**, Josefsson M, Apelqvist G, Ahlner J, Baumann P, Bengtsson F. Disposition of venlafaxine enantiomers in rats with hepatic encephalopathy after chronic drug treatment. *Chirality* 14(4) 347 - 350, 2002. **Facteur d'impact 1.6 (2002)**.
143. Bondolfi G, **Eap CB**, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. *Pharmacopsychiatry* 35(2); 50 – 56, 2002. **Facteur d'impact 1.8 (2002)**.
144. **Eap CB**, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary-Cosendai L, Jonzier-Perey M, Baumann P. Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine and the mephenytoin test. *Ther Drug Monitor* 23(3) 228-231, 2001. **Facteur d'impact 2.0 (2001)**.
145. **Eap CB**, Bondolfi G, Zullino D, Savary-Cosendai L, Powell-Golay K, Kosel M, Baumann P. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple dose of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. *J Clin Psychopharmacol* 21(3) 330-334, 2001. **Facteur d'impact 4.0 (2001)**.
146. Bart PA, Rizzardi GP, Gallant S, Python C, Pantaleo G, **Eap CB**. Methadone blood concentrations are decreased by the administration of abacavir and amprenavir. *Ther Drug Monitor* 23(5); 553-555, 2001. **Facteur d'impact 2.0 (2001)**.
147. **Eap CB**, Broly F, Mino A, Hämmig R, Déglon JJ, Uehlinger C, Meili D, Chevalley AF, Bertschy G, Zullino D, Kosel M, Preisig M, Baumann P. Cytochrome P-4502D6 genotype and methadone steady-state concentrations. *J Clin Psychopharmacol* 21(2) ; 229-234, 2001. **Facteur d'impact 4.0 (2001)**.
148. **Eap CB**, Bourquin M, Martin JL, Spagnoli J, Livoti S, Powell K, Baumann P, Déglon JJ. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. *Drug and Alcohol Dependence* 61(1) ; 47-54 2000
149. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, **Eap CB**, Baumann P. Cytochromes P-450 activities in human and rat brain microsomes. *Brain Research* 855(2); 235-243, 2000.

150. Bondolfi G, Lissner C, Kosel M, **Eap CB**, Baumann P. Fluoxetine augmentation in citalopram nonresponders: pharmacokinetic and clinical consequences. *Int J Neuropsychopharmacol* 3(1):55-60, 2000.
151. **Eap CB**, Bender S, Fischer W, Haarmann C, Powell K, Jonzier Perey M, Cochard N, Berger M, Gastpar M, Baumann P. Steady-state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. *Therapeutic Drug Monitoring* 22(2) :209-214, 2000.
152. **Eap CB**, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. *Therapeutic Drug Monitoring* 21:166-170,1999.
153. Felder C, Uelingher C, Baumann P, Powell K, **Eap CB**. Oral and intravenous methadone use: some clinical and pharmacokinetic aspects. *Drug and Alcohol Dependence* 55:137-143, 1999
154. Fjordside L, Jeppesen U, **Eap CB**, Powell K, Baumann P, BrØsen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. *Pharmacogenetics* 9:55-60, 1999.
155. Kosel M, **Eap CB**, Amey M, Baumann P. Analysis of the enantiomers of citalopram and its demethylated metabolites using chiral liquid chromatography. *J of Chromatogr. Biomed Appl.* 719:234-238, 1998.
156. **Eap CB**, Schnyder C, Besson J, Savary L, Buclin T. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. *Clin. Pharmacol. Ther.* 64:52-57,1998.
157. **Eap CB**, Bouchoux G, Cochard N, Savary L, Baumann P. Simultaneous determination of plasma levels of citalopram, paroxetine, sertraline, and their metabolites by gas chromatography-mass spectrometry. *J Chromatogr Sci* 36:365-371, 1998.
158. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, **Eap CB**, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. *Am J Psychiatry* 155:499-504, 1998.
159. **Eap CB**, Schnyder C, Buclin T, Savary L. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma by gas-chromatography-mass spectrometry. *J. Chromatogr. Biomed. Appl.* 705:139-144, 1998.
160. **Eap CB**, de Mendonça Lima C, Macciardi B, Woggon B, Powell K, Baumann P. Steady-state concentrations of the enantiomers of mianserin and desmethyl mianserin in poor and homozygous and heterozygous extensive metabolizers of debrisoquine. *Ther. Drug Monitor.* 20:7-13, 1998.
161. **Eap CB**, Powell K, Baumann P. Determination of the enantiomers of mianserin and metabolites in plasma by capillary electrophoresis after liquid-liquid extraction and on-column sample preconcentration. *J Chromatogr Sci* 35:315-320, 1997.
162. **Eap CB**, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. *J Clin Psychopharmacol* 17: 113-117, 1997.
163. **Eap CB**, Gaillard N, Powell K, Baumann P. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry *J. Chromatogr. Biomed. Appl.* 682: 265-272, 1996.
164. **Eap CB**, Finkbeiner T, Gaspar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. *Eur J Clin Pharmacol.* 50:385-389, 1996.
165. Bertschy G, **Eap CB**, Powell K, Baumann P. Fluoxetine addition to methadone in addicts-Pharmacokinetic aspects. *Ther. Drug. Monitor.* 18(5):570-572, 1996.
166. **Eap CB**, Guentert TW, Schäublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin patients. *Clin. Pharmacol. Ther.* 59:322-331, 1996.
167. Hervé F, Millot MC, **Eap CB**, Duché JC and Tillement JP. A two-step chromatographic purification of human plasma α 1-acid glycoprotein. Its application to the purification of rare phenotype samples of the protein and their study by chromatography on immobilized metal chelate affinity adsorbent. *J. Chromatogr. Biomed. Appl.* 678:1-14, 1996.
168. **Eap CB**, Koeb L, Powell K, Baumann P. Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma. *J. Chromatogr. Biomed. Appl.* 669:271-279, 1995.

169. **Eap CB**, Powell K, Campus Souche D, Monney C, Baettig D, Taeschner W, Baumann P. Determination of the enantiomers of mianserin, desmethyalmianserin, and 8- hydroxymianserin in the plasma and urine of mianserin-treated patients. *Chirality* 6:555-563, 1994.
170. Seifritz E, Holsboer-Trachsler E, Hemmeter U, **Eap CB**, and Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. *Eur. Neuropsychopharmacol.* 4: 15-20, 1994.
171. **Eap CB**, Koeb L, and Baumann P. Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. *J. Chromatogr. Biomed. Appl.* 652: 97-103, 1994.
172. Bertschy G, Baumann P, **Eap CB** and Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. *Ther. Drug. Monit.* 16: 42-45, 1994.
173. Yuasa I, Weidinger S, Umetsu K, Suenaga K, Ishimoto G, **Eap CB**, Duché JC, and Baumann P. Orosomuroid System: 17 additional orosomuroid variants and proposal for a new nomenclature. *Vox Sang* 64: 47-55, 1993.
174. Reymond P, Amey M, Souche A, Lambert S, Konrat H, **Eap CB**, and Baumann P. Determination of plasma levels of citalopram and its demethylated and deaminated metabolites by gas chromatography and gas chromatography-mass spectrometry. *J. Chromatogr. Biomed. Appl.* 616: 221-228, 1993.
175. **Eap CB**, Koeb L, and Baumann P. Artifacts in the analysis of thioridazine and other neuroleptics. *J. Pharm. Biomed. Anal.* 11: 451-457, 1993.
176. **Eap CB**, Koeb L, Holsboer-Trachsler E, and Baumann P. Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites. *Ther. Drug. Monit.* 14: 380-385, 1992.
177. **Eap CB**, Laurian S, Souche A, Koeb L, Reymond P, Buclin T, and Baumann P. Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers - A pilot study on two subjects. *Neuropsychobiology* 25: 214-220, 1992.
178. Van Dijk W, Pos O, Van der Stelt M, Moshage EHJ, Yap S H, Dente L, Baumann P, and **Eap CB**. Inflammation-induced changes in expression and glycosylation of genetic variants of alpha1-acid glycoprotein. Studies with human sera, primary cultures of human hepatocytes and transgenic mice. *Biochem. J.* 276: 343-347, 1991.
179. **Eap CB**, Souche A, Koeb L, and Baumann P. Light-induced racemization: artifacts in the analysis of the diastereoisomeric pairs of thioridazine 5-sulfoxide in the plasma and urine of patients treated with thioridazine. *Ther. Drug. Monit.* 13: 356-362, 1991.
180. **Eap CB**, Fischer JF, and Baumann P. Variations in relative concentrations of variants of human alpha1-acid glycoprotein after acute-phase conditions. *Clinica Chimica Acta* 203: 379-386, 1991.
181. **Eap CB**, Cuendet C, and Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha1-acid glycoprotein. *Clin. Pharmacol. Ther.* 47: 338-346, 1990.
182. Tomei L, **Eap CB**, Baumann P, and Dente L. Use of transgenic mice for the characterization of human alpha1-acid glycoprotein (orosomuroid) variants. *Hum. Genet.* 84: 89-91, 1989.
183. **Eap CB**, Cuendet C, and Baumann P. Binding of amitriptyline to alpha1- acid glycoprotein and its variants. *J. Pharm. Pharmacol.* 40: 767-770, 1988.
184. **Eap C B** and Baumann P. Isoelectric focusing of alpha1-acid glycoprotein (orosomuroid) in immobilized pH-gradients with 8 M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. *Electrophoresis* 9: 650-654, 1988.
185. **Eap CB**, Cuendet C, and Baumann P. Orosomuroid (alpha1-acid glycoprotein) phenotyping by use of immobilized pH gradients with 8 M urea and immunoblotting. *Hum. Genet.* 80: 183-185, 1988.
186. **Eap CB**, Cuendet C, and Baumann P. Selectivity in the binding of psychotropic drugs to the variants of alpha1-acid glycoprotein. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 337: 220-224, 1988.

Other papers (letters, responses, case studies, comments, reviews) published in peer reviewed journals

1. Schoretsanitis G, de Leon J, **Eap CB**, Kane JM, Paulzen M. Clinically significant drug-drug interactions with agents for attention-deficit/hyperactivity disorder. *CNS Drugs.* 2019 Dec;33(12):1201-1222. **Facteur d'impact 4.2 (2018)**
2. Fischer Fumeaux CJ, Morisod Harari M, Weisskopf E, **Eap CB**, Epiney M, Vial Y, Csajka C, Bickle Graz M, Panchaud A. Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and

- lactation based on best available evidence – an update (review). Expert opinion on Drug Safety 2019;18(10):949-963. **Facteur d'impact 3.2 (2018).**
3. **Eap CB.** Personalized prescribing : a new medical model for clinical implementation of psychotropic drugs (review). Dialogues in Clinical Neurosciences, 18 (No 3), 313-322, 2016. **Facteur d'impact 4.0 (2016).**
 4. Chen F, Richard S, D'Andrea G, Grandjean C, **Eap CB.** Accidentally detected asymptomatic Wolff-Parkinson-White syndrome in an adolescent with depression (case report). Swiss Archives of Neurology, Psychiatry and Psychotherapy 2016;167(3):94-96. **Facteur d'impact 2.9 (2016).**
 5. Paulzen M, **Eap CB,** Gründer G, Kuzin M. Pharmacokinetic Interaction between Valproic acid, Meropenem and Risperidone (case report). J Clin Psychopharmacol 2016 Feb; 36(1):90-2. **Facteur d'impact 2.3 (2016).**
 6. Liakoni E, Huber X, Crettol S, **Eap CB,** Liechti ME. Eine unerwünschte Wirkung von Methadon und Moxifloxacin (case report). Swiss Medical Forum 16(7):176–177, 2016
 7. Ansermot N, Chocron O, Herrera F, **Eap CB.** Severe manic episode associated with tramadol in a patient with recurrent depressive disorder (Case report). J Clin Psychopharmacol 2015; 35(2):203-4. **Facteur d'impact 3.0 (2015).**
 8. Weisskopf E, Fischer Fumeaux C, Bickle Graz M, Moriso Harari M, Tolsa JF, Vial Y, **Eap CB,** Csajka C, Panchaud A. Risk-benefit balance assessment of SSRI antidepressants use during pregnancy and lactation based on best available evidence (review). Expert Opinion on drug safety (2015) 14(3) :413-427. **Facteur d'impact 2.9 (2015).**
 9. Guessous I, **CB Eap,** Bochud M. Blood pressure in relation to coffee and caffeine consumption (review). Current Hypertension Rep 2014; 16:468. **Facteur d'impact 3.4 (2014).**
 10. Panchaud A, Weisskopf E, Winterfedl U, Baud D, **Eap CB,** Csajka C, Widmer N. Médicaments et grossesse: modifications pharmacocinétiques liées à la grossesse et place du suivi thérapeutique pharmacologique (revue) Thérapie 69(3): 223-34 (2014). **Facteur d'impact 0.5 (2014).**
 11. Ansermot N, Hodel PF, **Eap CB.** Serotonin syndrome after adjunction of mirtazapine to escitalopram (case report). J Clin Psychopharmacol 2014; 34(4):540-541. **Facteur d'impact 3.2 (2014).**
 12. Paulzen M, Henkel K, Tauber S, Reich A, **Eap CB,** Gründer G. Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a non-fatal overdose during a suicide attempt (case report). J Clin Psychopharmacol 2014; 34(3):398-399. **Facteur d'impact 3.2 (2014).**
 13. Crettol S, de Leon J, Hiemke C, **Eap CB.** Pharmacogenomics in psychiatry: from TDM to genomic medicine (review). Clin Pharmacol Ther 2014, 95(3):254-257. **Facteur d'impact 7.9 (2014).**
 14. Noetzi M, **Eap CB.** Pharmacodynamic, pharmacokinetic and pharmacogenetics aspects of drugs used in the treatment of Alzheimer's disease (review). Clin Pharmacokinetics 2013, 52:225-241. **Facteur d'impact 5.5 (2013).**
 15. tereoisomeric pairs of **EAP CB.** Addition of aripiprazole to the clozapine may be useful in reducing anxiety in treatment resistant-schizophrenia (case report). Case report in Psychiatry, volume 2011, article ID 846489, doi:10.1155/2011/846489
 16. Ansermot N, Albayrak Ö, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Faouzi M, Rey F, Scherbaum N, **Eap CB.** Letter « Does methadone prolong QTc interval by depleting testosterone levels? In Reply” Arch Int Med 170(15)1408, 2010. **Facteur d'impact 10.6 (2010).**
 17. Choong E, Dobrin M, Carrupt PA, **Eap CB.** The permeability glycoprotein: a focus on enantioselectivity and brain distribution (review). Expert Opinion on drug metabolism and toxicology 6(8), 953-965, 2010. **Facteur d'impact 3.4 (2010).**
 18. Oneda B, Preisig M, Dobrin M, **Eap CB.** Lack of associations between genetic polymorphisms of ARRB2 and alcohol dependence in a Caucasian population. (letter) Alcohol and alcoholism 45(6): 590-591, 2010. **Facteur d'impact 2.6 (2010).**
 19. Bochud M, Bovet P, Burnier M, **Eap CB.** CYP3A5 and ABCB1 genes and hypertension (review) Pharmacogenomics 10(3), 477-87, 2009. **Facteur d'impact 3.9 (2009).**
 20. Bochud M, **Eap CB,** Bovet P, Burnier M. La génétique de l'hypertension : rôle des gènes CYP3A5 et ABCB1 dans le contrôle de la tension artérielle (review). Médecine cardiovasculaire / Kardiovaskuläre Medizin 11(11) :353-60, 2008
 21. Crettol S, Schläpfer J, Abriel H, **Eap CB.** Response to “Methadone induced QTc prolongation. Is it due to stereoselective block of hERG or to inappropriate QT interval correction?” (Letter) Clin Pharmacol Ther 83(5) 672, 2008. **Facteur d'impact 7.6 (2008).**
 22. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, **Eap CB.** No influence of ABCB1 haplotype on methadone dosage requirement (Letter). Clin Pharmacol Ther 83(5) 668-669, 2008. **Facteur d'impact 7.6 (2008).**
 23. Dobrin M and **Eap CB.** Cytochrome P4503A pharmacogenetics (review). HIV-pharmacogenetics.org HIV PGX 2:2, 2007.

24. Crettol S, Monnat M, **Eap CB**. Could pharmacogenetic data explain part of the interindividual sensitivity to methadone-induced respiratory depression? (Commentary). *Critical Care* 11:119, 2007. **Facteur d'impact 3.8 (2007)**.
25. **Eap CB**. Pharmacokinetic and pharmacogenetic factors influencing methadone plasma levels. (Review). *Heroin addiction and related clinical problems* 9(2):39-46, 2007.
26. Baumann P, Barbe R, Vabre-Bogdalova A, Garran E, Crettol S, **Eap CB**. Epileptiform seizure following sertraline treatment in an adolescent suffering from obsessive compulsive disorder with CYP2B6 and CYP2D6 genetic deficiency (Letter). *J Clin Psychopharmacol* 26(6):679-681, 2006. **Facteur d'impact 4.6 (2006)**.
27. Jaquenoud-Sirot E, Willem van der Velden J, Rentsch K, **Eap CB**, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance (Review). *Drug safety*, 29(9) 735-68, 2006. **Facteur d'impact 3.7 (2006)**.
28. Holzer L, **Eap CB**. Aripiprazole and suicidality: a case report (letter). *Int Clin Psychopharmacol* 21(2) 125-126, 2006. **Facteur d'impact 3.1 (2006)**.
29. Stephan PL, Jaquenoud Sirot E, Mueller B, **Eap CB**, Baumann P. Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP3A4/5 activity: a pharmacovigilance case report (letter). *Pharmacopsychiatry* 39(4) 150-2, 2006. **Facteur d'impact 2.8 (2006)**.
30. Albrecht A, Morena P, Baumann P, **Eap CB**. High dose of depot risperidone in a non-responder schizophrenic patient (Letter). *J Clin Psychopharmacol* 24(6):673-4, 2004. **Facteur d'impact 4.4 (2004)**.
31. **Eap CB**, Jaquenoud Sirot E, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenetics studies (Review). *Ther Drug Monitor* 26 (2), 152-155 (2004). **Facteur d'impact 2.8 (2004)**.
32. Jaquenoud Sirot E, **Eap CB**, Baumann P. Bedeutung von TDM und Pharmakogenetik bei Untersuchungen über Arzneimittelsicherheit in der Psychiatrie (Review). *Psychopharmakotherapie* 10: 5-10, 2003. **Facteur d'impact 0.7 (2003)**.
33. Eich-Höchli D, Oppliger R, Powell-Golay K, Baumann P, **Eap CB**. Methadone maintenance treatment and St John's wort (Letter). *Pharmacopsychiatry*, 36: 35-37, 2003. **Facteur d'impact 2.8 (2003)**.
34. Baumann P, Zullino DF, **Eap CB**. Enantiomer's potential in psychopharmacology - A critical analysis with special emphasis on the antidepressant escitalopram (Review). *European Neuro Psychopharmacology* 12(5) 433 – 444, 2002. **Facteur d'impact 2.5 (2002)**.
35. Hilleret H, Voirol P, Bovier P, Giannakopoulos P, Zullino D, Baumann P, Giroud C, Rivier L, **Eap CB**. Very long half-life of paroxetine following intoxication in an extensive cytochrome P4502D6 metabolizer: a case report (Case report). *Ther Drug Monitor*, 24(4) 567-569, 2002. **Facteur d'impact 2.1 (2002)**.
36. Fellay J, Back D, Schinkel AH, **Eap CB**, Telenti A. Multidrug resistance and response to antiretroviral treatment (Correspondence). *The Lancet*, 359: 2114-2115, 2002. **Facteur d'impact 15.4 (2002)**.
37. Zullino DF, Delessert D, **Eap CB**, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine and olanzapine (Case report). *Int. Clin Psychopharmacol*, 17(3) 141-143, 2002. **Facteur d'impact 2.8 (2002)**.
38. **Eap CB**, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone : implications for the treatment of opioid dependence (Review). *Clinical Pharmacokinetics* 41:1153-1193, 2002. **Facteur d'impact 4.2 (2002)**.
39. Baumann P, **Eap CB**, Zullino D. Fluvoxamine and perphenazine for psychosis in alzheimer's disease: pharmacokinetic considerations (Letter). *The Journal of nervous and mental disease*, 189(11) 798-799, 2001. **Facteur d'impact 1.5 (2001)**.
40. Zullino D, **Eap CB**, Voirol P. Ondansetron in the treatment of tardive dyskinesia (Letter). *Am J Psy* 158(4) 657-658, 2001. **Facteur d'impact 6.9 (2001)**.
41. Baumann P, **Eap CB**. Enantiomeric antidepressant drugs should be considered on individual merit (Review). *Hum Psychopharmacol Clin Exp* 16(S2) S85-S92, 2001. **Facteur d'impact 1.0 (2001)**.
42. **Eap CB**, Bertel-Laubscher R, Amey M, Baumann P. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report (Case report). *Pharmacopsychiatry* 33(3) 112-115, 2000.
43. **Eap CB**. Opiate withdrawal symptoms induced by antiretroviral drugs in patients receiving methadone (Letter). *Annals of Pharmacotherapy* 34(9) ; 1077-1078, 2000.
44. Leavitt SB, Shindermann M, Maxwell S, **Eap CB**, Paris P. When « enough » is not enough: New perspectives on optimal methadone maintenance dose (Review). *Mount Sinai Journal of Medicine* 67(5-6): 404-411, 2000.
45. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, **Eap CB**. Efavirenz decreases methadone blood concentrations (Letter). *AIDS* 14(9) : 1291-1292, 2000.

46. Voirol P, **Eap CB**, Baumann P. Monitoring thérapeutique des psychotropes et tests pharmacogénétiques en psychiatrie (Review). *Revue Médicale de la Suisse Romande* 120(2) ; 99-104, 2000.
47. **Eap CB**. On the usefulness of therapeutic drug monitoring of methadone (Letter). *European Addiction Research* 6(1) :31-33, 2000
48. **Eap CB**, Déglon JJ, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance (Review). *Heroin addiction and related clinical problems* 1:19-34, 1999
49. Baumann P, Broly F, Markus K, **Eap CB**. Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2D6 genotyping (Letter). *Pharmacopsychiatry* 31:72, 1998.
50. Bender S. and **Eap CB**. Very high cytochrome P450IA2 activity and non-response to clozapine (Letter). *Archives of General Psychiatry* 55:1048-1050,1998
51. **Eap CB**, Buclin T, Buchwalder PA, Gutmann N, Baumann P. Multiple and simultaneous phenotyping tests: beware of ascorbic acid when determining the mephenytoin (S)/(R) ratio (Letter). *Clinica Chimica Acta* 271:105-107, 1998
52. **Eap CB**, Bertschy G, Finkbeiner T, Gastpar M, Scherbaum N, Baumann P. High interindividual variability of methadone enantiomer blood levels to dose ratios (Letter). *Archives of General Psychiatry* 55:89-90, 1998.
53. Bondolfi G, Rubin C, Bryois C, **Eap CB**. Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report (Letter). *Thérapie* 352:76-77 1997
54. **Eap CB**, Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients (Review). *J. Chromatogr. Biomed. Appl.* 686: 51-63, 1996.
55. Conus P, Bondolfi G, **Eap CB**, Macciardi F, Baumann P. Pharmacokinetic fluvoxamine-clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient (Case report). *Pharmacopsychiatry* 29:108-110, 1996.
56. Baumann P, Hatzinger M, U. Hemmeter, E. Seifritz, **Eap CB**, Holsboer E. Influence of amesergide treatment on the dextromethorphan test (Letter). *Br J Clin Pharmacol* 38:151-152, 1994.

Other papers published for didactic purposes in journals without peer review

1. Crettol Wavre S, Ansermot N, Sibailly G, Vandenberghe F, Grandjean C, Robalo BT, Fassassi Gallo S, Thonney J, Solida-Tozzi A, Conus P, **Eap CB**. Agitation aiguë chez l'adulte : proposition d'un algorithme de traitement psychopharmacologique. *Rev Med Suisse* 2020; 16 :1751-5
2. **Eap CB**. Les antidépresseurs sont-ils efficaces ? : Oui. *Psychoscope* 2018. Page 34
3. Weisskopf E, Fumeaux CF, Bickle Graz M, Harari MM, Epiney M, Tolsa CB, Rouiller S, Tolsa J-F, Vial Y, **Eap CB**, Csajka C, Panchaud A. Le bon usage des antidépresseurs ISRS durant la grossesse- le défi de l'évaluation de la balance bénéfico-risque. *Revue médicale Suisse* 2016 Mar 16 ;12(510):561-6
4. Conus P, Herrera F, Berney S, Gailland B, Beretta V, Vandenberghe F, **Eap CB**. New developments in psychiatry. *Revue Médicale Suisse* 2016; 13 Jan, 12(500) :86-9
5. Crettol S & **Eap CB**. Cytochrom-P450-Genotypisierung: ein Instrument zur Personalisierung der medikamentösen Behandlung in der Psychiatrie. *Pipette* 2013; N°6: Theme 10-11
6. Panchaud A, Csajka C, Weisskopf E, Vial Y, Lepigeon K, Tolsa JF, Bickel – Graz M, Fischer C, **Eap CB**, Moriso Harari M. Etude multicentrique: "antidépresseurs, grossesse et allaitement". *Forum (Société Suisse de Gynécologie et d'Obstétrique* 2/13, pages 03-06, 2013.
7. Crettol S, **Eap CB**. Cytochromes P450: génotypes et/ou phénotypes pour l'individualisation du traitement médicamenteux. *Pipette*, 1, Février 2013, pp 10-11
8. Conus P, Despland J-N, Herrera F, Chanachev A, **Eap CB**, Mall JF, Ebbing K, von Gunten A. *Psychiatrie. Revue Médicale Suisse* 9 Janvier 2013, p 76-79.
9. Rentsch K, Buhl D, **Eap CB**, Fathi M, Thormann W, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). *J Lab med* 36(2):77-88, 2012.
10. Guex P, Conus P, Pomini V, Kramer U, Bonsack C, **Eap CB**. Nouveautés en médecine 2010 – Psychiatrie. *Revue Médicale Suisse* 278 (7) : 150-153, 2011
11. Chanachev A, Conus P, **EAP CB**. La pharmacogénétique / pharmacogénomique en psychiatrie : perspectives théoriques et perspectives pour l'avenir. *L'Information Psychiatrique* 87(9) :697-703, 2011
12. Solida A, Choong E, Lechaire C, **Eap CB**, Conus P. Syndrome métabolique et antipsychotiques atypiques : recommandations et prise en charge clinique. *L'Information Psychiatrique* 87(9) :715-724, 2011
13. Rentsch K, Buhl D, **Eap CB**, Fathi M, Thormann W, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). *J Lab med* 35 (2):81-91, 2011.

14. Rossier MF, Rebsamen M, Crettol S, **Eap CB**, Rentsch K. Evidence based medicine for pharmacogenetics. *Pipette* (4). Aout 2010, Thème 13
15. Rentsch K, Buhl D, **Eap CB**, Fathi M, Jöchle W, Magnin JL, Thormann W, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). *J Lab med* 34 (3):129-39, 2010.
16. Rentsch K, **Eap CB**, Fathi M, Grignaschi N, Magnin JL, Thormann W, Todesco L, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). *J Lab med* 33(2):99-120, 2009
17. Dobrinas M, Cornuz J, Kohler Serra M, Puhl M, **Eap CB**. Aspects génétiques de la consommation de tabac et impact sur la prise en charge clinique (review). *Revue Médicale Suisse* 5: 1463-1467, 2009
18. Rentsch K, **Eap CB**, Fathi M, Grignaschi N, Magnin JL, Thormann W, Todesco L, Werner D. Monographs on drugs which are frequently analyzed in therapeutic drug monitoring (review). *J Lab med* 32(5):372-81, 2008
19. Besson J, **Eap CB**, Khazaal Y, Montagrin Y, Rihs-Middel M, Simon O, Tissot H, Tomei A, Zumwald C, Zullino D. Nouveautés en médecine 2007: Dépendances. *Revue médicale Suisse*, 139 : 8 – 13, 2008.
20. Choong E, Solida A, Lechaire C, Conus P, **Eap CB**. Suivi du syndrome métabolique induits par les antipsychotiques atypiques: Recommandations actuelles et perspectives futures basées sur les études pharmacogénétiques. *Revue Médicale Suisse* 4 :1994-9, 2008
21. **Eap CB**. Méthadone et cardiotoxicité. Rapport annuel de la Fondation Phenix 2008
22. Widmer N, Csajka C, Werner D, Grouzmann E, Decosterd LA, **Eap CB**, Biollaz J, Buclin T. Suivi thérapeutique des médicaments (review, part I) : les principes. *Rev Med Suisse* 4: 1644-8, 2008.
23. Widmer N, Werner D, Grouzmann E, **Eap CB**, Csajka C, Marchetti O, Fayet A, Csajka C Decosterd LA, Buclin T. Suivi thérapeutique des médicaments: la pratique clinique (review, part II) *Rev Med Suisse* 4 :1649 - 60, 2008
24. Besson J, **Eap CB**, Rougemont-Buecking A, Simon O, Nikolov C, Bonsack C, Gothuey I. (review) Acquisitions thérapeutiques 2005: Dépendances *Revue Médicale Suisse*, 2(47) 9-13, 2006
25. **Eap CB**. Apport de la Pharmacogénétique dans la prise en charge médicamenteuse des addictions. *THS La Revue des Addictions*. Vol VI (no 23), Septembre 2004, p 1173-1175.
26. Jacquenoud Sirot E, **Eap CB**, Baumann P. Die Bedeutung des therapeutischen Drug Monitoring (TDM) und der Pharmacogenetik bei Untersuchungen über Arzneimittelsicherheit in der Psychiatrie. *AGNP-TDM Magdeburg* 2002
27. De Mendonça Lima CA, **Eap CB**, Baumann P. La psychopharmacothérapie dans le domaine de la psychogériatrie : actualité, problèmes, perspectives (Review). *Revue Médicale de la Suisse Romande* 120 (2);131-136, 2000.
28. **Eap CB**. Nouvelles études psychopharmacologiques sur la méthadone : implications pour le traitement de la dépendance aux opiacés (Review). *Revue Médicale de la Suisse Romande* 120(2) ; 111-116, 2000.
29. **Eap CB**, Déglon JJ, Baumann P. Metadone: farmacocinetica e farmacogenetica. *Italian Journal of the Addictions*, 1999, Mars 22-23, 41-47.
30. Baumann P, **Eap CB**. Mechanismen und klinische Bedeutung von pharmakokinetischen Interaktionen. *Medizinpiegel. Ärztejournal für die Schweiz*, 1999, 6, 25-28
31. **Eap CB**. Résistance à un traitement antidépresseur. Importance et intérêt du monitoring thérapeutique et de la pharmacogénétique. *Compte rendu du XVIIe congrès de l'Association pour la Promotion des Hôpitaux de Jour pour Personnes Agées (APHJPA)*, 5-6 Juin 1997, Prilly-Lausanne.
32. Baumann P. and **Eap CB**. Genetics, biochemistry, physiological functions, and pharmacology of alpha1-acid glycoprotein. *Académie Suisse des Sciences Naturelles XIII*: 32-34, 1989.
33. Baumann P. and **Eap CB**. Rapport du Congrès international: Genetics, biochemistry, physiological functions, and pharmacology of alpha1-acid glycoprotein. *Bulletin de l'Académie Suisse des Sciences Médicales* 77-79, 1989.

Book chapters, editing, monographies

1. Besson M, **Eap CB**, Schaad N. *Vademecum psychiatrie* (in press)
2. Bertholet L, Do KQ, Schenk F, Ansermot N, **Eap CB**. Un regard sur la schizophrénie *Actualités Psychologiques* 2009-22 (Introduction à la Neurosciences psychiatrique : appui de cours). pp. 77-106, 2009
3. Giroud C, **Eap CB**, Favrat B, Sporkert F, Augsburg M, Rochat B, Montoya JP, Castella V, Mangin P. Impact of oral cannabis on driving skills and genetic vulnerability to psychotic symptoms. *XV Mosbacher*

symposium der GTFCh. April 2007 Mosbach Baden Germany.
<http://www.gtfch.org/cms/index.php/proceedings/162-tagungsband-zum-xv-gtfchsymposium-1821042007-in-mosbach>

4. Crettol S and **Eap CB**. Pharmacogenomics of opioids. In "Pharmacogenomics and proteomics: Enabling the practice of personalized medicine". M Linder, R Valdes, SH Wong (ed). American Association of Clinical Chemistry press, chapter 19, pages 187-198, 2006.
5. **Eap CB**, Déglon JJ, Baumann P. Pharmacokinetics and pharmacogenetics of methadone: clinical relevance. Heroin assisted treatment. Swiss Federal Office of Public Health (Health Sciences). Verlag Hans Huber. Chapter 27, pages 251-265 (2005).
6. **Eap CB**, Baumann P. Apport de la pharmacogénétique dans le traitement médicamenteux des addictions : l'exemple de la méthadone. Federal Office of Public Health. Recherches de l'OFSP en matière de dépendances 2002-2003, Volume 1/3 : Recherche Fondamentale, page 65-69, 2005
7. **Eap CB**. Apport de la Pharmacogénétique dans la prise en charge médicamenteuse des addictions. Acte du colloque THS Toxicomanies, Hépatites, Sida. Volume 1 (Addictions et Toxicomanies), Editions Frison-Roche (Paris). Pages 103-108 (2004)
8. Uchtenhagen A, Ali R, Berglund M, Brenneisen R, **Eap CB**, Farell M, Mattick R, McLellan T, Rehm J, Simpson D. Methadone as a medicine for the management of opioid dependence and HIV/AIDS prevention. Geneva, World Health Organisation, 2004
9. **Eap CB**, Baumann P. Pharmacologie clinique et Pharmacogénétique de la méthadone. Federal Office of Public Health. Recherches de l'OFSP en matière de dépendances 1999-2001. Vol 1/3 Recherche fondamentale, page 52-56, 2003.
10. **Eap CB**. Variabilité interindividuelle de la réponse thérapeutique aux médicaments de substitution : le cas de la méthadone. THS La revue des Addictions. Publication trimestrielle de la Société Européenne Toxicomanies, Hépatites, Sida. Actes du colloque THS (Toxicomanies, Hépatites, Sida) 5. Editions Frison-Roche, Paris, 2002, 149 – 157.
11. Baumann P, Zullino D, **Eap CB**. Pharmakokinetik und therapeutisches Monitoring von Antidepressiva. In: Depression 2000 (G Laux ed.). Bayer-ZNS-Symposium XVI. Springer Verlag Berlin Heidelberg 2002. Chapter four, 37 – 50.
12. Baumann P, Zullino DF, Jaquenoud Sirot E, Paus E, **Eap CB**. Therapy with antidepressants: pharmacogenetics aspects. In Advances in Biological Psychiatry (Vol 21) Perspectives in affective disorders, Wolfgang Kaschka (ed) Karger, Basel, 2002, Vol 21, 95 – 111.
13. Baumann P. and **Eap CB**. Pharmacogenetics of chiral psychotropic drugs. In "Pharmacogenetics of psychotropic drugs" Cambridge University Press. Bernard Lerer (ed). 2002; 181-214.
14. **Eap CB**, Voirol P, Baumann P, de Mendonça Lima C. Prescription des antidépresseurs chez la personne âgée : A propos de quelques spécificités. Collection : L'année gérontologique (Serdi Edition), V. Camus, L Schmitt (rédacteurs). 2001, 131-150.
15. **Eap CB**, Baumann P. Pharmacocinétique et pharmacogénétique de la méthadone. Federal Office of Public Health. Recherches de l'OFSP en matière de dépendances 1996-98, Volume 1 / 4 : Recherche fondamentale, April 2000, 16-19.
16. **Eap CB**, Bertschy G, Baumann P. Pharmacogenetics of methadone. Federal Office of Public Health (in press)
17. Baumann P, **Eap CB**, Steimer W, Kosel M, Voirol P. Ultraschnelle Metabolisierer: Grundlagen and klinische Bedeutung. Psychopharmakotherapie, 1999, vol 2, 62-64
18. Baumann P, **Eap CB**, Voirol P. Clinical pharmacokinetics of SSRIs. In « Selective Serotonin Reuptake inhibitors (SSRIs) : Past, present and future. S. Clare Stantford (Ed) R.G. Landes Company, Austin, Texas, USA (Publisher). Page 9 - 27 (1999).
19. Baumann P, **Eap CB**, de Mendonça Lima C, Zullino D. Characteristics of psychotropic drug metabolism in geriatric patients. In « Mental Disorders in the Elderly: New Therapeutic Approaches ». Brunello N, Langer SZ, Racagni G (eds). Int Acad Biomed Drug Res Basel, Karger, 1998, Vol 13, pp 159-170.
20. **Eap CB**, Bertschy G. Méthadone : nouveaux aspects. Office Fédéral de la Santé Publique. Aertzliche Verschreibung von Betäubungsmitteln: Praktische Umsetzung (PROVE-Band II)
21. **Eap CB**, Bertschy G, Baumann P. Analyse de la méthadone dans le plasma. Dans « Recherches de l'OFSP en matière de dépendances ». Office Fédéral de la Santé Publique (1997)
22. **Eap CB** and Baumann P. The alpha1-acid glycoprotein: structure and possible functions in the acute phase response. In: *Acute phase proteins. Molecular biology, biochemistry, and clinical application*, edited by A. Mackiewicz, I. Kushner, and H. Baumann. Boca Raton: CRC Press, 1993, p. 107-116.
23. Baumann P. and **Eap CB**. Klinische Relevanz pharmakogenetischer Phänotypisierungen. In: *Biologische Psychiatrie der Gegenwart. 3. Drei-Länder Symposium für Biologische Psychiatrie, Lausanne,*

September 1992, edited by P. Baumann, W. W. Fleischhacker, W. Gaebel, G. Laux, H. J. Möller, B. Saletu, and B. Woggon. Wien, New York: Springer-Verlag, 1993, p. 658-663.

24. **Eap CB**, Souche A, Koeb L, and Baumann P. Light-induced racemization of the diastereoisomeric pairs of thioridazine 5-sulfoxide: origin of artifacts in the TDM of thioridazine. In: *Recent developments in therapeutic drug monitoring and clinical toxicology.*, edited by I. Sunshine. New York: Marcel Dekker, Inc., 1992, p. 111-115.
25. Baumann P and **Eap CB**. Therapeutic drug monitoring: role of alpha1-acid glycoprotein (AGP) binding. In: *Recent developments in therapeutic drug monitoring and clinical toxicology.* edited by I. Sunshine. New York: Marcel Dekker, 1992, p. 153-157.
26. Baumann P. and **Eap CB**. Plasma monitoring of antidepressants: clinical relevance of the pharmacogenetics of metabolism and of alpha1-acid glycoprotein binding. *Biological Psychiatry* 1: 362-364, 1991.
27. **Eap CB** and Baumann P. Pharmacogenetics of drug binding to albumin and alpha1-acid glycoprotein. In: *Plasma binding of drugs and its consequences*, edited by F. Belpaire, M. Bogaert, J. -P. Tillement, and R. Verbeeck. Ghent: Academia Press, 1990, p. 69-82.
28. **Eap CB** and Baumann P. The genetic polymorphism of human alpha1-acid glycoprotein. In: *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology*, edited by P. Baumann, C. B. Eap, W. E. Müller, and J. -P. Tillement. New York: Alan R. Liss, Inc., 1989, p. 111-125
29. Bree F, **Eap CB**, Baumann P, Duche JC, and Tillement JP. Comparison of drug binding capacities of two AAG peptidic variants of human origin. In: *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology*, edited by P. Baumann, C. B. Eap, W. E. Müller, and J. -P. Tillement. New York: Alan R. Liss, Inc., 1989, p. 399-403.
30. Baumann P. and **Eap CB**. Das saure alpha1-Glycoprotein: ein Modell zum Studium der Eiweissbindung von psychotropen Pharmaka. In: *Biologische Psychiatrie*, edited by B. Saletu. Stuttgart, New York: Georg Thieme Verlag, 1989, p. 358-361.
31. Baumann P. and **Eap CB**. Contribution of the variants of alpha1-acid glycoprotein to its binding of drugs. In: *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions, and pharmacology*, edited by P. Baumann, C. B. Eap, W. E. Müller, and J. -P. Tillement. New York: Alan R. Liss, Inc., 1989, p. 379-397.
32. Baumann P, **Eap CB**, Müller WE and Tillement JP. *Alpha1-acid glycoprotein: genetics, biochemistry, physiological functions and pharmacology.* New York: Alan R. Liss, Inc., 1989, p. 1-469.

Abstracts

1. Grosu C, Trofimova O, Pistis G, Strippoli M-P, Preisig M, Draganski B, **Eap CB**. CYP2C19 expression, hippocampal volume and influence on global functioning. Alpine Brain Imaging Meeting, 12-16 January 2020. Champéry, Switzerland.
2. Rios-Leyvraz M, Bochud M, Tabin R, Genin B, Russo M, **Eap CB**, Bovet P, Chiolerio A. how monitor caffeine intake in children? A comparison between questionnaire and 24-h urine excretion. Swiss Public Health Conference, August 2019, Winterthur, Switzerland
3. Glatard A, Guidi M, Dubath C, Grosu C, Laaboub N, von Gunten A, Conus P, Csajka C *, **Eap CB** *. Amisulpride: Real-World Evidence of dose adaptation and effect on Prolactin levelsemia using PK/PD modeling. Population Approach group Europe (PAGE) congress. * joint corresponding authors 11-14 June 2019 Stockholm Sweden.
4. **Eap CB**. Pharmacogenetics in psychiatry: the case of antidepressants. WFSBP, Vancouver, Canada, 2-6 June 2019
5. Crettol S, Ansermot N, Vandenberghe F, **Eap CB**. Combining TDM and pharmacogenomics: some examples WFSBP, Vancouver, Canada, 2-6 June 2019
6. Dubath C, Delacrétaz A, Glatard A, Vollenweider P, Preisig M, Richard-Lepouriel H, Hasler R, Gamma F, Solida A, Thonney J, Fassassi S, von Gunten A, Conus P, **Eap CB**. Cardiometabolic health: where do we stand? Evaluation of risk in a large psychiatric cohort and comparison with a population-based sample in Switzerland. WFSBP Vancouver 2-6 June 2019
7. Lenski M, Allorge D, **Eap CB**, Thomas A. Prise de poids induite par les psychotropes : Contribution d'une méthode de métabolomique ciblée pour identifier de potentiels biomarqueurs prédictifs. SFTA 22-24 May 2019
8. **Eap CB**. Clinical determinants of the metabolic syndrome induced by psychotropic drugs. 27th European Congress of Psychiatry, Warsaw, Poland, 6-9 April, 2019
9. Glatard A, Guidi M, Delacrétaz A, Dubath C, Levier A, Conus P, Von Gunten A, **Eap CB***, Csajka C*. Amisulpride dose adaptation with age and lean body weight in adult and elderly psychiatric patients. GSASA 2018 meeting (Fribourg, Switzerland) *shared last co-authorship

10. Glatard A, Guidi M, Delacrétaz A, Dubath C, Levier A, Conus P, von Gunten A, **Eap CB***, Csajka C*. Population pharmacokinetic model of amisulpride for individual dosing in psychiatric patients. Population Approach group Europe (PAGE) Congress, Montreux, Switzerland, June 2018. PAGE 27, (2018) Abstract N° 8460 * joint corresponding authors
11. Courlet P, Guidi M, Glatard A, Cavassini M, Buclin T, Marzolini C, **Eap CB**, Decosterd LA, Csajka C. Comparison of escitalopram pharmacokinetics in HIV infected individuals with an uninfected psychiatric cohort. Population Approach group Europe (PAGE) Congress, Montreux, Switzerland, June 2018. PAGE 27, (2018) Abstract N° 8460
12. Vandenberghe F, Delacrétaz A, Ambresin A-E, von Gunten A, Conus P, **Eap CB**. Importance of early metabolic changes to predict long-term weight gain and dyslipidemia during psychotropic drug treatment. Swiss Society of Pharmacology and Toxicology Spring Meeting 2018 and Swiss Society of Clinical Pharmacology and Therapeutics Annual Conference, Bern, Switzerland, Mai 2018
13. Alameda L, levier A, Golay P, Gholam-Rezaee M, Dubath C, Delacrétaz A, Vandenberghe F, Do KQ, **Eap CB**, Conus P. Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in early psychosis patients independently of medication. Schizophrenia International Research Society Conference, SIRS 2018, Florence, Italy, April 2018. Schizophr Bull. 2018;44(Suppl. 1):S310. Abstr. F227
14. Conus P, Fournier M, Xim L, Cleusix M, Baumann PS, Ferrari C, Cousins A, Alameda L, Gholam-Rezaee M, Golay P, Jenni R, Wilson Woo TU, Keshavan M, **Eap CB**, Wojcik J, Cuenod M, Buclin T, Gruetter R, Seidman L, Do K. An add-on trial with N-acetyl-cysteine (NAC) in early psychosis patients: Towards biomarker guided treatment. Schizophrenia International Research Society Conference, SIRS, Florence, Italy, April 2018. Schizophr Bull. 2018;44(Suppl. 1):S236. Abstr. F44
15. Saigi-Morgui N, Vandenberghe F, Delacrétaz A, Quteineh L, Gholam-Rezaee, Kutalik Z, Aubry JM, Von Gunten A, Conus P, **Eap CB**. Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. 23rd Annual world congress of Psychiatric Genetics (WCPG) Toronto, Canada Oct 16-20, 2015. European Neuropsychopharmacology Vol: 27 (Suppl. 2) pages: S248-S249, 2017. Abstract Su82
16. **Eap CB**, Crettol S, Ansermot N. Pharmacogenetics in Psychiatry. WFSBP congress, Copenhagen, Denmark, June 2017.
17. Glatard A, Guidi M, Dobrinas M, Cornuz J, Csajka C *, **Eap CB** * Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population. Population Approach group Europe (PAGE) congress, Budapest, Hungary, June 2017. * Equal contribution
18. Levier A, Saigi Morgui N, Delacrétaz A, Vandenberghe F, Glatard A, Gholam-Rezaee M, Panczak R, von Gunten A, Conus P, **Eap CB**, Association of body mass index with socioeconomic factors in a Swiss psychiatric cohort WFSBP Copenhagen, June 2017.
19. Delacrétaz A, Vandenberghe F, Saigi Morgui N, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, **Eap CB**, Importance of early changes of blood lipid levels to predict long-term dyslipidemia during psychotropic drug treatment. WFSBP Copenhagen, June 2017.
20. Delacrétaz A, Santos Lagares P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, Gamma F, von Gunten A, Conus P, **Eap CB**, Importance of polygenic risk scores to predict lipid levels and dyslipidemia development in a psychiatric population taking dyslipidemia-inducing psychotropic drugs. WFSBP Copenhagen, June 2017.
21. Ansermot N *, Bochatay M *, Schläpfer J, Gholam-Rezaee Mohammad M, Gonthier A, Conus P, **Eap CB**. Etude rétrospective sur le suivi électrocardiographique (ECG) des patients hospitalisés en psychiatrie adulte. Journées franco-suisse de pharmacie hospitalière (JFSPH), Berne, Suisse, 1-2 décembre 2016. Le Pharmacien Hospitalier et Clinicien Vol 52 issue 1, Abstract R-PCL-36, March 2017 * Contribution équivalente
22. Do K Q, Seidman L. J, Fournier M, Xin L., Cleusix M, Baumann P S, Ferrari C, Cousins A, Alameda L, Gholam-Rezaee M, Golay P, Jenni R, Woo T-U W, Kashavan M S, Eap CB, Wojcik J, Cuenod M, Buclin T, Gruetter R., Conus P. N-acetyl-cysteine in a double-blind randomized placebo-controlled trial : toward biomarker-guided treatment in early psychosis. 16th International Congress on Schizophrenia Research (ICOSR) San Diego, USA, March 24-28, 2017. Schizophrenia Bulletin 2017, Vol:43(Suppl. 1) Abstract SA19, pages S119-S120.
23. Conus P, Fournier M, Xin L., Baumann PS, Ferrari C, Cousins A, Alameda L, Golay P, Jenni R, Kashavan M S, Eap CB, Cuenod M, Buclin T, Gruetter R, Seidman L, Do KQ. N-Acetyl-Cysteine in a double blind randomized placebo controlled trial: towards biomarker guided treatment in early psychosis. 25th European Congress of Psychiatry, 2017. European Psychiatry 2017, 41(Suppl. S) Abst. EV1230. Pages: S806
24. Berney S, **Eap CB**, Conus P, Solida A. A case of at-risk mental state after exposition to LSD and

- isotretinoin. IEPA 10th. Early intervention in Mental Health, Milan, 20-22 October 2016, Vol 10 (Supl S1):225, Abstract C100.
25. Glatard A, Guidi M, Dobrinas M, Cornuz J, Csajka C*, **Eap CB***. Influence of *UGT2B7* polymorphism on varenicline clearance in a cohort of smokers from the general population. Population approach group Europe (PAGE) Meeting, 7-10 June 2016, Lisboa, Portugal, 2016 *Joint corresponding author
 26. **Eap CB**, Crettol S, Sibailly G, Ansermot N. TDM and pharmacogenetics for improving psychiatric patient care: the situation in Lausanne, Switzerland. XIIth Symposium of the AGNP Task Force on Therapeutic Drug Monitoring in Psychiatry, Bremen, Germany, 1-3 June 2016. *Pharmacopsychiatry* 2016; 49(3):128, Abstract 017
 27. Marie-Claire, C. Crettol S, Cagnard N, Bloch V, Mouly S, Laplanche J-L, Bellivier F, Lépine JP, **Eap CB**, Vorspan F. Genome-wide DNA Methylation Comparison Between High Versus Low Dose Stabilized Methadone Maintained. Annual meeting society of Biological Psychiatry, Atlanta, USA, May 2016
 28. Liakoni E, Huber X, Stegert M, Crettol S, **EAP CB**, Liechti ME. Torsades de pointes due to co-administration of methadone and moxifloxacin. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), Madrid, Spain. May 2016. *Clinical Toxicology* 54(4): 428, Abstract 135, 2016
 29. Weisskopf E, Panchaud A, Csajka C, **Eap CB**. Placental transfer of antidepressant medications and the effect of maternal and fetal drug transporter polymorphisms. 20th North American Meeting of ISSX Orlando, USA, Oct 18-22, 2015. *Drug Metabolism Reviews* 48 Suppl. 1 pages: 130-131, 2016
 30. Jordanov V, Smogur M, Holzer L, **Eap CB** Ansermot N. Adolescent psychotropic drug use in a Swiss psychiatric university hospital: retrospective studies in 2008 and 2014 GSASA Zurich November 2015
 31. Bachmann T, Vandenberghe F, Saigi Morgui N, Delacrétaz A, von Gunten A, Conus P, **Eap CB**. Pharmacogenetic study on type 2 diabetes induced by psychotropic drugs. GSASA Zurich November 2015
 32. Guessous I, Tanica Lyngdoh, Pruijm M, Ponte B, Ackermann D, Ehret G, Ansermot N, Vuistiner P, Staessen J, Gu Y, Paccaud F, Mohaupt M, Vogt B, Pechère-Berstchi A, Martin PY, Burnier M, **Eap CB**, Bochud M. Associations of serum lipids with serum and urinary caffeine and caffeine metabolites in non-smokers. 2015 Swiss Public Health meeting.
 33. Guessous I, Pruijm M, Ponte B, Ehret G, Ansermot N, Vuistiner P, Staessen JA, Gu YM, Paccaud F, Mohaupt MG, Vogt B, Pechère-Berstchi A, Martin PY, Burnier M, **Eap CB**, Bochud M. Ambulatory pulse pressure is negatively associated with excretions of urinary caffeine and its metabolites. *Journal of Hypertension* 2015 jun ; 33(Suppl 1):e10-1, article N° 1C.06
 34. Saigi Morgui N, Vandenberghe F, Delacrétaz A, Quteineh L, Gholam-Rezaee M, Kutalik Z, Aubry JM, von Gunten A, Conus P, **Eap CB**. Association of Genetic Risk Score with Body Mass Index in Swiss psychiatric cohorts World Congress of Psychiatric genetics , Toronto, Canada October 2015
 35. Delacrétaz A, Preisig M, Vandenberghe F, Saigi Morgui N, Quteineh L, Choong E, Gholam-Rezaee M, Kutalik Z, Magistretti P, Aubry J-M, von Gunten A, Castelao E, Vollenweider P, Waeber G, Conus P, **Eap CB**. Influence of *MCHR2* and *MCHR2-AS1* genetic polymorphisms on body mass index in psychiatric patients and in subjects from the general population with present or past atypical depression. 12th World Congress of Biological Psychiatry, Athens, Greece, June 14-18, 2015
 36. Saigi Morgui N, Vandenberghe F, Delacrétaz A, Quteineh L, Gholam-Rezaee M, Kutalik Z, Aubry JM, von Gunten A, Conus P, **Eap CB**. Influence of Weighted Genetic Risk Score on BMI in Swiss psychiatric cohorts. 12th World Congress of Biological Psychiatry, Athens, Greece, June 14-18, 2015
 37. Quteineh L, Vandenberghe F, Saigi Morgui N, Delacretaz A, Choong E, Gholam-Rezaee M, Magistretti P, Bondolfi G, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Bochud M, Kutalik Z, Conus P, **Eap CB**. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients with psychotropic treatments. 12th World Congress of Biological Psychiatry, Athens, Greece, June 14-18, 2015
 38. Vandenberghe F; Saigi Morgui N, Quteineh L, Gholam Rezaee M, von Gunten A, Conus P, **Eap CB**. Clinical and genetic markers to predict a rapid and strong weight gain during psychotropic treatment. 12th World Congress of Biological Psychiatry, Athens, Greece, June 14-18, 2015
 39. **Eap CB**. Pharmacogenetics to improve pharmacotherapies. 12th World Congress of Biological Psychiatry, Athens, Greece, June 14-18, 2015

40. Vandenberghe F, Saigi Morgui N, Delacrétaz A, Quteineh L, von Gunten A, Conus P, **Eap CB**. Genetic and clinical determinants of weight gain and/or metabolic syndrome in a large psychiatric sample treated with psychotropic drugs. 168th American Psychiatric Association (APA) Annual Meeting in Toronto, Canada, May 16-20, 2015.
41. Ansermot N, Smogur M, Holzer L, **Eap CB**. Prescription de médicaments psychotropes chez des adolescents hospitalisés en milieu psychiatrique. 2ème congrès Suisse de pharmaciens, Interlaken, 3-4 novembre 2014
42. **Eap CB**. Pharmacogenetics in psychiatry: is there clinical relevance ? 1st German Conference for laboratory medicine, September 24th - 27th, 2014 in Mannheim, Germany
43. Guessous I, Pruijm M, Ponte B, Ackermann D, Ehret G, Vuistiner P, Paccaud F, Burnier M, **Eap CB**, Bochud M: Ambulatory blood pressure is associated with urinary caffeine and caffeine metabolites excretions Swiss Public Health Conference 2014 “Public Mental Health”, Olten, Switzerland, 2014
44. **Eap CB**. Use of therapeutic drug monitoring in psychiatry. XVI world congress of psychiatry, Madrid, September 2014. Symposium novel approach to personalized medicine in psychiatry. Lecture on “Use of therapeutic drug monitoring in psychiatry”
45. Dahmane E, Zaman K, Decosterd L, **Eap CB**, Perey L, Bodmer A, Leyvraz S, Galmiche M, Buclin T, Guidi M, Csajka C. Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients. Meeting of the population approach group Europe, Alicante, Spain, 2014.
46. Dahmane E, Zaman K, Perey L, Bodmer A, Leyvraz S, **Eap CB**, Galmiche M, Decosterd L, Buclin T, Guidi M, Csajka C. Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients. Annual meeting of the Swiss Society of Internal Medicine / Swiss Society of Clinical Pharmacology, Geneva, May 2014
47. Quteineh L, Vandenberghe F, Gholam-Rezaee M, Choong E, Saigi Morgui N, Delacretaz A, Preisig M, von Gunten A, Conus P, **Eap CB**. *CRTC3* polymorphisms are not associated with obesity in Swiss Psychiatric populations. 22nd European Congress of Psychiatry, Munich, Germany, March 2014. *European Psychiatry* 2014; 29 Suppl. 1 EPA-1390.
48. Vandenberghe F, Gholam-Rezaee M, Choong E, Saigi Morgui N, Quteineh L, Delacretaz A, Preisig M, von Gunten A, Conus P, **Eap CB**. Predictive values of appetite and early weight increase for long-term weight variation during psychotropic treatment. 22nd European Congress of Psychiatry, Munich, Germany, March 2014. *European Psychiatry* 2014; 29 Suppl.1, EPA-1389.
49. Alwan H, Pruijm M, Ackermann D, Guessous I, Ehret G, Vuistiner P, Paccaud P, Pechère-Bertschi A, Mohaupt M, Vogt B, Martin PY, Burnier M, **Eap CB**, Bochud M, Ponte B. Caffeine levels are inversely associated with kalemia in women : a population based study. Swiss Society of Nephrology
50. Crettol Wavre S, Ansermot N, **Eap CB**. From therapeutic drug monitoring to pharmacogenetics 10th Annual Conference of the DGKL, October 23rd - 26th, 2013 in Dresden, Germany. *Clin Chem Lab Med* 2013; 51(10): eA4
51. Dahmane E, Zaman K, Perey L, Bodmer A, Leyvraz S, **Eap C B**, Galmiche M, Decosterd L, Buclin T, Guidi M, Csajka C. Population Pharmacokinetics of Tamoxifen and three of its metabolites in Breast Cancer patients Population approach group in Europe, 22nd meeting, Glasgow, June 2013.
52. **Eap CB**. Pharmacogenetics as a means of individualizing drug treatment in psychiatry. World Federal Association of Biological Psychiatry. Kyoto June 2013.
53. Crettol S, Ansermot N, Dobrinas M, Csajka C, **Eap CB**. Genetic-based pharmacokinetics and cardiotoxicity of methadone. Abstract from the International Society of Addiction Medicine, 14th Annual Meeting 14-18 October 2012, Geneva, Switzerland (oral presentation by S Crettol at the young investigator meeting), *The Canadian Journal of Addiction Medicine* 4(2):7, 2013.
54. Guessous I, Pruijm M, Ponte B, Ackermann D, Ehret G, Vuistiner P, Paccaud F, Mohaupt M, Vogt B, Pêche-Bertschi A, Martin PY, Burnier M, **Eap CB**, Bochud M. Caffeine is negatively associated with systolic blood pressure in non-smokers. *European Society of Hypertension*, Milano, Italy, 2013
55. Zaman K, Dahmane E, Perey L, Bodmer A, Anchisi S, Wolfer A, Galmiche M, Stravodimou A, Buclin T, **Eap CB**, Decosterd L, Csajka C. and Leyvraz S. Tamoxifen dose escalation based on endoxifen levels a prospective trial with genotyping, phenotyping and pharmacokinetics over 4 months. San Antonio Breast Cancer Symposium. (Dec 4-8, 2012). *Cancer Research* 72 Suppl. 24, Abstract P6-04-05, 2012
56. Ansermot N, Hodel PF, **Eap CB**. Serotonin syndrome after adjunction of mirtazapine to escitalopram. Congrès annuel de la GSASA (Association suisse des pharmaciens de l'administration et des hôpitaux), Baden, November 2012

57. Crettol S, Ansermot N, Dobrinas M, Csajka C, **Eap CB**. Genetic-based pharmacokinetics and cardiotoxicity of methadone. International Society of Addiction Medicine (ISAM), 14Th Annual Meeting 14-18 October 2012, Geneva, Switzerland (oral presentation by S Crettol at the young investigator meeting).
58. Jaquenoud Sirot E, Harenberg S, Vandiel P, Mendonça Lima CA, Perrenoud P, Kemmerling K, Zullino DF, Hilleret H, Crettol S, Jonzier-Perey M, Powell Golay K, Brocard M, **Eap CB** and Baumann P. Clinical effectiveness, pharmacokinetics and pharmacogenetics of mirtazapine in depression. Psychotropic Drug: Risks und Risk management: Xth Congress of the interdisciplinary TDM Task Force of the AGNP together with Swiss Society for Pharmacovigilance in Psychiatry (SGMSP) and Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP). Brugg, Switzerland, 26th-28th September 2012. *Pharmacopsychiatry* 45 (6): 253, 2012.
59. Jaquenoud Sirot E, Stephan P, **Eap CB**, Van der Velden JW, Baumann P. Matched case-control study: therapeutic drug monitoring in pharmacovigilance. Psychotropic Drug: Risks und Risk management: Xth Congress of the interdisciplinary TDM Task Force of the AGNP together with Swiss Society for Pharmacovigilance in Psychiatry (SGMSP) and Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP). Brugg, Switzerland, 26th-28th September 2012. *Pharmacopsychiatry* 45 (6): 253, 2012.
60. Paulzen M, Henkel K, Tauber S, Reich A, **Eap C B**, Gründer G. Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a non-fatal overdose during a suicide attempt. Xth Congress of the interdisciplinary TDM Task Force of the AGNP together with Swiss Society for Pharmacovigilance in Psychiatry (SGAMSP) and Swiss-Austrian Chapter of the International Society of Pharmacovigilance (ISoP). Brugg, Switzerland, 26th-28th September 2012. *Pharmacopsychiatry* 45 (6) : 255, 2012
61. Vandenberghe F, Choong E, Saigi Morgui N, Quteineh L, Ambresin AE, von Gunten A, Conus P, **Eap CB**. Clinical study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, August 2012
62. Jaquenoud Sirot E, Stephan P, **Eap CB**, Van der Velden JW and Baumann P. Nested case-control study in psychiatric in patients: AMSP+. 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, August 2012
63. Eap CB, Vandenberghe F, Choong E, Saigi Morgui N, Ambresin AE, Von Gunten A, Conus P. Clinical and pharmacogenetic study on psychotropic drug induced weight gain and other metabolic complications in a Swiss psychiatric population. 28th World congress of CINP (International College of Neuropsychopharmacology), Stockholm, Sweden, 3-7 June 2012. *International Journal of Neuropsychopharmacology* 15 (Suppl. 1): 101, 2012. Abstract P-06-002
64. Paulzen M, Henkel K, Tauber S, Reich A, **Eap CB**, Gründer G. Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a non-fatal overdose during a suicide attempt. 28th World congress of CINP (International College of Neuropsychopharmacology), Stockholm, Sweden, 3-7 June 2012. *International Journal of Neuropsychopharmacology* 15, Suppl. 1: 104 Abstract P-06-012, 2012
65. Guidi M, Vandenberghe F, Choong E, Buclin T, **Eap CB**, Csajka C. Population pharmacokinetics of risperidone and 9-OH risperidone in psychiatric patients. Population Approach Group Europe (PAGE), Venice, Italy (June 2012).
66. Vandenberghe F, Choong E, Saigi Morgui N, Quteineh L, Ambresin AE, Von Gunten A, Conus P, **Eap CB**. Clinical study on psychotropic drug induced weight gain and other metabolic complication in a Swiss psychiatric population. 28th World congress of CINP (International College of Neuropsychopharmacology), Stockholm, Sweden 3-7 June 2012.
67. Crettol S, Ansermot N, Csajka C, **Eap CB**. Genetics of methadone pharmacokinetics and cardiotoxicity: an update. 10th European Congress of the European Opiate Addiction Treatment Association. Barcelona, May 2012
68. Ansermot N, M Brawand Amey, **Eap CB**. Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring: Journées franco-suissees de pharmacie hospitalière à Lons-le-Saunier (France), March 2012.
69. Zaman K, Perey L, Dahmane E, Bodmer A, Wolfer A, Galmiche M, Stravodimou A, Buclin T, Csajka C, **Eap CB**, Decosterd L, Leyvraz S. Improving endoxifen level in breast cancer patients by increasing tamoxifen dose to 40 mg in CYP2D6 poor (PM), intermediate (IM) and extensive metabolizers (EM): a prospective, open-label trial. Am Soc Clin Oncology 2012 meeting
70. Dahmane E, Zaman K, Galmiche M, Berthod G, Perey L, Bodmer A, Leyvraz S, **Eap CB**, Decosterd L, Buclin T, Csajka C. Impact of tamoxifen dose on tamoxifen and its active metabolite

- exposure in breast cancer patients: preliminary results of a prospective open label trial. SGIM Basel May 2012
71. Csajka C, Crettol Wavre S, Guidi M, **Eap CB**. Genetic based population pharmacokinetics of R- and S-methadone and relationship with QT interval in opioid dependent patients. 1er Congrès Suisse des Pharmaciens GSASA, Interlaken, Nov 2011
 72. Noetzli M, Choong E, Ansermot N, **Eap CB**. Simultaneous determination of antimentia drugs by HPLC-MS: validation data of the method and plasma level determination in 300 patients. Abstract 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology Stuttgart, Germany. October 2-6, 2011. Therapeutic Drug Monitoring 33(4):501,P077, 2011
 73. Dobrinas M, Cornuz J, Oneda B, Kohler Serra M, Puhl M, **Eap CB**. Cytochrome P450 1A2 activity and inducibility: impact of smoking, smoking cessation and genetic polymorphisms. Abstract 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology Stuttgart, Germany. October 2-6, 2011. Therapeutic Drug Monitoring 33(4):473, O16, 2011
 74. Choong E, Conus P, Gaillard M, von Gunten A, Holzer L, Aubry JM, Etter M, Bondolfi G, Gholam Rezaee M, Preisig M, Eap CB, Clinical and pharmacogenetics studies on response and side-effects under psychotropic drugs. 14ème Journée de recherche des Départements de Psychiatrie de Genève et de Lausanne, june 2011, Prilly, Switzerland
 75. Lechaire C, Conus P, **Eap CB**. Case report: management of long acting intramuscular of risperidone induced hyperprolactinemia by adjonction of aripiprazole. 4th World Congress on Women's mental health. March 2011, Madrid, Spain
 76. Choong E, Bondolfi G, Etter M, Oneda B, Tayebi H, Aubry JM, **Eap CB**. Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers. Swiss Society Biological Psychiatry, Lausanne January 2011.
 77. Choong E, Rudaz S, Kottelat A, Guillaume D, Veuthey JL, Eap CB. Quantification of Bupropion, Hydroxy-Bupropion, Moclobemide Reboxetine and Trazodone by LC-MS for Therapeutic Drug Monitoring 27th Montreux symposium on LC/MS, November 2010, Montreux, Switzerland
 78. Ansermot N, Albayrak Ö, Schläpfer J, Crettol S, Croquette-Krokar M, Bourquin M, Déglon JJ, Faouzi M, Scherbaum N, **Eap CB**. Substitution of (R,S)-methadone by (R)-methadone: impact on QTc interval. Annual meeting Swiss Society of Clinical Pharmacology and Therapeutics. Lausanne, September 2010.
 79. Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hämmig R, Monnat M, Preisig M, **Eap CB**. β -arrestin2 influences the response to methadone in opioid dependent patients. Annual meeting Swiss Society of Clinical Pharmacology and Therapeutics. Lausanne, September 2010.
 80. Zaman K, Dahmane E, Perey L, Buclin T, Berthod G, Bodmer A, Galmiche M, Leyvraz S, **Eap CB**, Csajka C, Decosterd L. Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen. 33rd San Antonio breast cancer symposium (2010)
 81. Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hämmig R, Monnat M, Preisig M, **Eap CB** β -arrestin2 influences the response to methadone maintenance treatment. Annual meeting of the Swiss Society of Clinical Pharmacology and Toxicologie (Lausanne, Sep 2010)
 82. Crettol S, Ansermot N, Rouget JS, Albayrak Ö, Sintra-Grilo L, Monnat M, Besson J, Croquette-Krokar M, Schläpfer J, Bourquin M, Hämmig R, Déglon JJ, Scherbaum N, Abriel H, **Eap CB**. Pharmacological, pharmacogenetics and clinical studies on methadone: a "From the bench to the bedside" paradigm
 83. Choong E, Bondolfi G, Etter M, Oneda B, Tayebi H, **Eap CB**. Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers. 16th World Congress of Basic and Clinical Pharmacology, (WorldPharma 2010), Copenhagen, Denmark, 17-23 July 2010
 84. Bondolfi G, Choong E, Etter M, Oneda B, Tayebi H, Aubry JM, **Eap CB**. Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers. ECNP Amsterdam September 2010.
 85. Bondolfi G, Choong E, Etter M, Oneda B, Tayebi H, Aubry JM, **Eap CB**. Pharmacogenetic study on metabolic syndrome induced by atypical antipsychotics and mood stabilizers. Eur Congress of Biological Psychiatry. Berlin, 2010
 86. Dahmane E, Csajka C, Decosterd L, Mercier T, Zanolari B, **Eap CB**, Buclin T, Galmiche M, Zaman K. Tamoxifen metabolism and the impact of tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients. 09-2009 in "Frontiers in drug discovery and development": 24ème séminaire, 3ème cycle, en sciences pharmaceutiques
 87. Rudaz S, **Eap CB**, Ansermot N, Veuthey JL. Analyse chirale de la méthadone, du développement analytique au suivi thérapeutique. Abstract 4èmes Journées Internationales de Toxicologie - Liege 15-16 octobre 2009

88. Dilulio J, Fayet A, Rotger M, Colombo S, Cavassini M, Günthard H, **Eap CB**, Telenti A, Descosted L. Pharmacological and pharmacogenetic interactions in individuals receiving raltegravir. Abstract CHUV Research day January 29, 2009, César Roux Auditorium, "Genes and Diseases", page 50, 2009
89. Ansermot N, Rudaz S, Brawand-Amey M, Fleury-Souverain S, Veuthey JL, **Eap CB**. Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R,S)-methadone in clinical samples. TIAFT, Genève
90. Crettol S, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Déglon J.J, Oneda B, Preisig M, **Eap CB**. Association of dopamine and opioid receptor genetic polymorphism with response to methadone maintenance treatment Swiss Addiction Research Day III, 21 Nov 2008, Bern, Switzerland
91. Choong E, Rudaz S, Kottelat A, Guillarme D, Veuthey JL, **Eap CB**. Simultaneous determination and quantification of 7 psychotropic drugs and 4 metabolites in human plasma by HPLC-MS for therapeutic drug monitoring. 25th Symposium on Liquid Chromatography – Mass Spectrometry. Montreux, Switzerland, Nov 08
92. **Eap CB**, Crettol S, Rougier JS, Schlöpfer J, Sintra Grilo L, Déglon JJ, Besson J, Croquette-Krokar M, Carrupt PA and Abriel H. Stereoselective Block of hERG Channel by (S)-Methadone and QT Interval Prolongation in CYP2B6 Slow Metabolizer: evidence of a safer cardiac profile of (R)-methadone. Regensburg (Sept 08). Pharmacopsychiatry 2008;41(5):207
93. Jaquenoud Sirot, E, Knezevic, B, Morena PG, Baumann P, **Eap C B**. Pharmacogenetics of clozapine: In vivo role of cytochrome P450 isoforms and P-glycoprotein. 5th Regensburg Symposium on Clinical of Therapeutical Drug Monitoring/8th Workshop of the TDM Workgroup of AGNP, Regensburg, Germany, Sep 24-27, 2008. Pharmacopsychiatry 21(5):211, 2008 Abstract A-18
94. Daali Y, Samer C, **Eap C**, Rebsamen M, Rossier M, Dayer P, Desmeules J. Micrococktail validation for CYP3A and CYP2D6 assessment using a low dose of midazolam (0.075 mg) and dextromethorphan (2.5 mg). 76e assemblée annuelle de la Société Suisse de Médecine Interne. Beaulieu Lausanne 21-23 mai 08, Forum Médical Suisse 8(Suppl 40) 80S, 2008
95. **Eap CB**. Genotyping to optimize antipsychotic drug treatment. XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP), München, Germany Int J Neuro psychopharmacol 11 (Suppl.1) 2008, p 86. EWS-03.01
96. Jaquenoud Sirot E, Knezevic B, Morena PG, Baumann P, **Eap CB**. *ABCB1* and *cytochromes P450* genotypes and phenotypes: influence on clozapine plasma concentrations. IX World conference on Clinical Pharmacology and Therapeutics. Quebec City, Canada, July 27 – August 1, 2008. The Canadian Journal of Clinical Pharmacology 2008; 15(3) e465-e466.
97. Di Lulio J, Rotger M, Lubomirov R, Decosterd L, **Eap CB**, Telenti A. Genetic variation in accessory metabolic pathway is associated with extreme efavirenz exposure in individuals with impaired CYP2B6 function. CROI 15th conference on retroviruses and opportunistic infections. Boston (USA) 2008.
98. Rotger M, di Lulio J, Lubomirov R, Decosterd L, **Eap CB**, Telenti A. Functional polymorphisms in alternative metabolic pathways (*CYP3A* and *CYP2A6*) lead to extreme efavirenz exposure in individuals with limited CYP2B6 function. Pharmacogenetic meeting of Cold Spring, USA, 2007.
99. Daali Y, Samer C, **Eap CB**, Rebsamen M, Rossier M, Dayer P, Desmeules J. Micro-cocktail validation for CYP3A and CYP2D6 assessment using a low dose of midazolam (0.075 mg) and dextromethorphan (2.5 mg). Schweiz med Forum 2007;7(Suppl. 35), 84S.
100. Widmer N, Leyvraz S, Duchosal MA, Rosselet A, Csajka C, Henry H, Debiec-Rychter M, **Eap CB**, Biollaz J, Buclin T, Decosterd LA. Clinical consequences imatinib plasma concentrations variability in hemato-oncologic patients. 10th International Congress of therapeutic drug monitoring & Clinical Toxicology, Nice, France September 2007. Ther Drug Monit 2007; 29(4) 481.
101. Giroud C, **Eap CB**, Favrat B, Sporkert F, Augsburg M, Rochat B, Buclin T, Castella V, Mangin P. Impact of oral cannabis on driving skills and genetic vulnerability to psychotic symptoms. XV Mosbacher symposium der GTFCh. April 2007 Mosbach Baden Germany. Toxicchem + Krimtech (2007) 74 (1) 19.
102. Daali Y, Samer C, **Eap CB**, Rebsamen M, Rossier M, Dayer P, Desmeules J. Micro-cocktail validation for CYP3A and CYP2D6 assessment using a low dose of midazolam (0.075 mg) and dextromethorphan (2.5 mg). Annual meeting of the American Society for Clinical Pharmacology and Therapeutics, Mar 21-24, 2007. Clinical Pharmacology and Therapeutics 81: p S77,2007 (ASCPT), Anaheim (USA)

103. Giroud C, **Eap CB**, Favrat B, Augsburger M, Mangin P, Castella V. Are *CYP*, *UGT*, *CNBR1*, *DRD2*, *COMT* and *ABCB1* gene polymorphisms contributing to cannabis and dronabinol vulnerability to psychotic symptoms? Society of Forensic Toxicologists Austin, Texas, USA, 2006.
104. Jaquenoud Sirot E, Etzensberger M, **Eap CB**, Baumann P. Dose-dependent venlafaxine induced hair loss. International Society of Pharmacovigilance. Liège, Belgium. October 2006. Abstract Drug Safety 29(10) pp 939.
105. Bochud M, **Eap CB**, Maillard M, Elston RC, Bovet P, Shamlaye C, Burnier M. The *ABCB1* 2677G>T and 3435 C>T variants are associated with changes of glomerular filtration rate in African families. 39th Annual Renal Week Meeting of the American Society of Nephrology November 2006, San Diego, California.
106. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Gottuey I, Hämmig R, Monnat M, Brocard M, Cochard N, Brawand M, **Eap CB**. Pharmacogenetics of the metabolism of methadone enantiomers. Internantional Conference on Pharmacogenetics IUPHAR & PRACP, Changsha, China, June 2006.
107. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Gottuey I, Hämmig R, Monnat M, Brocard M, Cochard N, Brawand M, **Eap CB**. Impact of the C957T polymorphism of dopamine D2 receptor on response to treatment in methadone maintenance treatment. Internantional Conference on Pharmacogenetics IUPHAR & PRACP, Changsha, China, June 2006.
108. Samer C, Daali Y, **Eap CB**, Hopfgartner G, Rossier M, Rebsamen M, Chiappe A, Hochstrasser D, Dayer P, Desmeules J. Pivotal role of CYP2D6 and CYP3A4 pathways on the pharmacodynamics of oxycodone. Swiss Society of Internal Medicine meeting 2006.
109. Colombo S, Buclin T, Décosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, **Eap CB**. Orosomucoid plasma concentration and genetic variants: effects on HIV protease inhibitors clearance and cellular accumulation ratio. 7th International workshop on clinical Pharmacology in HIV therapy (April 2006, Lisbon, Portugal).
110. Crettol S, Venetz JP, Aubert JD, Fontana M, Brocard M, Pascual M, **Eap CB**. Genetic polymorphisms of CYP3A genes affect cyclosporine A blood concentration and dose requirement in transplant recipients. World Transplant Congress, Boston, USA, 2006. Transplantation, 82 (Suppl 3) 197, 2006.
111. Crettol S, Venetz JP, Aubert JD, Fontana M, Ansermot N, Fathi M, Brocard M, Pascual M, **Eap CB**. Influence of MDR1 genetic polymorphisms on intralymphocyte concentrations of cyclosporine A in transplant recipients. World Transplant Congress, Boston, USA, 2006. Transplantation, 82 (Suppl 3): 197, 2006.
112. Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, **Eap CB**, Henry H and Buclin T. Relation entre la pharmacocinétique de population de l'imatinib et l'alpha-1 glycoprotéine acide chez des patients hémato-oncologiques. 13^{ème} Journée Franco-Suisses de pharmacie hospitalière 2006
113. Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, **Eap CB**, Henry H and Buclin T. Relationship between imatinib population pharmacokinetics and alpha-1-acid glycoprotein. Swiss Society of Internal Medicine, Lausanne 2006.
114. Colombo S, Buclin T, Décosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J, **Eap CB**. Orosomucoid level and genetic variants: effects on HIV protease inhibitors clearance and cellular accumulation. Swiss Society of Internal Medicine, Lausanne 2006.
115. Baumann P, Jaquenoud Sirot E, **Eap CB**. Optimisation of psychopharmacotherapy: Clinical relevance of pharmacogenetic tests and therapeutic drug monitoring. AGNP, München, Sept. 2005. Pharmacopsychiatry 38(5) 229, 2005.
116. Sarueva RB, Andovona I E, Genova JA, Horvath AD, Simeonov VA, **Eap CB**, Garev V S. Balkan endemic nephropathy and genetic variants of xenobiotic metabolizing enzymes. 9th International Conference on environmental Science and Technology Rhodes, Greece Sep 1-3 2005. Proceedings of the International Conference on Environmental Science and Technology A1307-A1311, 2005
117. **Eap CB**. Pharmacokinetics and pharmacogenetics of methadone. 5th Congress of the Italian Society of Addiction (Plenary lecture) Bari, Italy May 2005. Società Italiana Tossicodependenze pp 52-53, 2005.
118. Baumann P, Jaquenoud Sirot E, **Eap CB**. Risques, précautions et interactions à considérer dans le cadre d'une pharmacothérapie moderne de la schizophrénie. 7^{ème} symposium international sur la schizophrénie. Berne Mars 2005.
119. Lind AB, Reis M, Bengtsson F, Ahlner J, **Eap CB**, Baumann P, Dahl ML. CYP2D6 genotype in relation to steady state concentrations of mirtazapine, N-desmethyl mirtazapine and their

- enantiomers. Influence of CYP2B6 polymorphism on the steady-state plasma levels of the enantiomers of methadone. 7th Congress of the European Association of Clinical Pharmacology. Poznan (Poland), June 2005. Basic and Clinical Pharmacology and Toxicology, Volume 97(Suppl.1), p 124, 2005
120. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gottuey I, Hämmig R, Monnat M, Hüttemann H, Brocard M, Baumann P, **Eap CB**. Influence of CYP2B6 polymorphism on the steady-state plasma levels of the enantiomers of methadone. 7th Congress of the European Association of Clinical Pharmacology. Poznan (Poland), June 2005. Basic and Clinical Pharmacology and Toxicology, Volume 97, (Suppl. 1), p 121, 2005
 121. Bochud M, **Eap CB**, Elston RC, Bovet P, Schild L, Maillard M, Burnier M. The CYP3A5 polymorphism is associated with ambulatory blood pressure increase with age in families of African descent. 15th European meeting on hypertension, Milano (Italy), June 2005. Journal of Hypertension, 23(Suppl. 2), S367, 2005.
 122. Bochud M, **Eap CB**, Maillard M, Elston RC, Bovet P, Schild L, Burnier M. The CYP3A5 polymorphism is associated with urinary sodium excretion in families of African descent. 15th European meeting on hypertension, Milano (Italy), June 2005. Journal of Hypertension, 23(Suppl.2), S364, 2005.
 123. Baumann P, Jaquenoud Sirot E, **Eap CB**. Genetic polymorphisms of psychotropic drug metabolizing enzymes: clinical relevance. 13th Association of European Psychiatrists. München, Germany April 2005. Affective Disorders / European Psychiatry 20:S 103 (2005) Abstract. S-15-01.
 124. **Eap CB**. Drug monitoring during substitution treatment. 13th Association of European Psychiatrists. München, Germany April 2005. European Psychiatry 20(Suppl. 1) pp 15-16, 2005.
 125. **Eap CB**. Therapeutic Drug Monitoring of psychotropic drugs in the era of pharmacogenetics studies. 13th Association of European Psychiatrists. München, Germany April 2005. European Psychiatry 20(Suppl.1) pp 208-209, 2005.
 126. Le Bloc'h Y, Stigler M, **Eap CB**, Baumann P, Khazaal Y, Zullino D. Quetiapine in Cluster B personality disorder. American Psychiatric Association (APA), Atlanta 2005
 127. **Eap CB**, Bochud M, Elston RC, Bovet P, Maillard M, Burnier M. Association between the CYP3A5 A698G polymorphism and blood pressure in individuals of East African descent. CHUV Research Day 2005. Abstract book p 145
 128. Baumann P, Nikisch G, **Eap CB**. Plasma-CSF concentrations relationship of psychotropic drugs. TDM and pharmacogenetic tests as tools in pharmacovigilance, Lausanne, sept 04. Pharmacovigilance in Psychiatry. Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs. Pharmacopsychiatry; 38(1) 43, 2005.
 129. Holzer L, **Eap CB**, Halfon O, Baumann P. High sedation with low doses of atypical antipsychotics in 3 young patients (13 to 14 years old). International meeting, Lausanne, sept 1-3, 2004. Pharmacovigilance in Psychiatry. Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs. Pharmacopsychiatry; 38(1) 53, 2005.
 130. **Eap CB** and Baumann P. Will genotyping and phenotyping methods replace TDM in the future ? TDM and pharmacogenetic tests as tools in pharmacovigilance, Lausanne, sept 04. Pharmacovigilance in Psychiatry. Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs. Pharmacopsychiatry; 38(1) 48, 2005.
 131. Jaquenoud Sirot E, **Eap CB**, Baumann P. Follow-up of a Pharmacovigilance study in Psychiatry involving TDM and Pharmacogenetic Testing Lausanne, Sept 04. Pharmacovigilance in Psychiatry. Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs. Pharmacopsychiatry, 38(1) 54-55, 2005.
 132. Jaquenoud Sirot E, Stephan P, Knezevic B, **Eap CB**, Baumann P. TDM and pharmacogenetic tests as tools in pharmacovigilance, Lausanne, sept 04. Pharmacovigilance in Psychiatry. Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs. Pharmacopsychiatry; 38(1) 54, 2005.
 133. **Eap CB** and Baumann P. The role of pharmacogenetics in the pharmacological treatment of psychiatric disorders. Drei Länder Symposium, Berne Oct 04. European Archives of Psychiatry and Clinical Neurosciences, 254 (Suppl. 1), I/13, 2004.
 134. **Eap CB**. Pharmacogenomic of methadone. 6th EUROPAD (European Opiate Addiction Treatment Association) European Conference, Paris Nov. 04.
 135. Baumann P, **Eap CB**, Jaquenoud Sirot E. Die Bedeutung der Pharmakogenetik für die Psychopharmakotherapie. Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfall Gesellschaft, Berlin Nov 04. Der Nervenarzt, 75 (Suppl. 2), S322, 2004.

136. Baumann P, Jaquenoud Sirot E, **Eap CB**. Therapeutic drug monitoring and pharmacogenetics of psychotropic drugs German congress of clinical chemistry (Nov 04). *Clinical Chemistry and Laboratory Medicine* 42 (10) S12B, 2004, pp A116.
137. Jaquenoud Sirot E, **Eap CB**, Baumann P. Pharmacovigilance study in psychiatry involving TDM and pharmacogenetics. *Drei Länder Symposium*, Berne Oct 04. *European Archives of Psychiatry and Clinical Neurosciences*, 254 (Suppl. 1) I22, 2004.
138. Bochud M, **Eap CB**, Elston RC, Bovet P, Maillard M, Burnier M. The CYP3A5 polymorphism is associated with daytime ambulatory systolic blood pressure (SBP) in families of East African Descent. *American Society of Nephrology Meeting*, St Louis, 2004
139. Camus D, Bonsack C, Kaufmann N, **Eap CB**. Drug urine screening of psychiatric inpatients. *ENMESH 2004 (Inclusion and mental health in the new Europe)*. Congress Londres 2004.
140. Jaquenoud Sirot, E. Stephan, P. Knezevic, B. **Eap, C. B.** Baumann, P. TDM and pharmacogenetic tests as tools in pharmacovigilance 4th Annual Meeting (ISop), Dublin-Ireland Oct 06-08, 2004. *Drug Safety* 27(2):937, 2004
141. Jaquenoud Sirot E, **Eap CB**, Baumann P. Follow-up study using TDM and pharmacogenetic testing as tools in pharmacovigilance. 4th Annual Meeting (ISop), Dublin-Ireland Oct 06-08, 2004. *Drug Safety* 27(12):937, 2004
142. Jaquenoud Sirot E. **Eap CB**, Baumann P. Follow-up of a pharmacovigilance study in psychiatry involving TDM and pharmacogenetic testing. 20th International Society of Pharmacoepidemiology and Drug Safety (Bordeaux, France, August 2004).
143. Giroud C, Michaud K, Sporkert F, **Eap CB**, Augsburg M, Mangin P. Analyse de la cocaïne et de ses métabolites par TurbolonSpray LC-MS sur une colonne Atlantis® d'interaction hydrophile. Illustration de la méthode par un cas de surdosage. Réunion de la SFTA 2004.
144. **Eap CB**, Bondolfi G, Benmebarek M, Devaud C, Gex-Fabry M, Gravier B, Jaquenoud Sirot E, Cucchia G, Allorge D, Broly F, Baumann P. Du monitoring thérapeutique des médicaments, de la pharmacogénétique, du tabac et du jus de pamplemousse. Journée de recherche VD-GE, Juin 04
145. Baumann P, Jaquenoud Sirot E, Nikisch G, Paus E, **Eap CB**. TDM of chiral psychotropic drugs: basic and clinical aspects, ESCNP Trieste, Italie, May 2004. *Journal of Neural Transmission*, 111(5), XXIII, 2004.
146. Mathe A A, Agren H, Nikisch G, **Eap C B**, Brawand Amey M, Czernik A, Baumann P. Neuropeptide Y and Corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopran. SCNP (Scandinavian College of Neuropsychopharmacology) Abstracts. *Nord J Psychiatry* 58(2):101 Abstract 29, 2004.
147. **Eap CB**, Jaquenoud-Sirot E, Baumann P. Therapeutic monitoring of antidepressants in the era of pharmacogenomics. 8th International Congress of TDM-CT, Basel, Switzerland September 2003. Abstract S3-2.
148. Paus E, Jonzier-Perey M, Cochard N, **Eap CB**, Baumann P. Enantio-selective LC-MS analysis of mirtazapine, desmethyilmirtazapine and 8-hydroxymirtazapine in plasma of psychiatric patients. 8th International Congress of TDM-CT, Basel, Switzerland September 2003. *Ther Drug Monitor*, 25, p 493, 2003.
149. **Eap CB** and Baumann P. Einfluss metabolischer Prozesse auf den Verlauf und die Behandlung der Opioidabhängigkeit. Influence of metabolic processes on course and treatment of opioid-dependence. Abstract for the AGNP, München, September 2003. *Pharmacopsychiatry* 2003; 36, 222 (abstract no 59)
150. Baumann P, Jaquenoud Sirot E, **Eap. CB**. Interactions between somatic and psychotropic drugs: pharmacokinetic and pharmacodynamic consequences. Interaktionen zwischen somatischen und psychotropen Pharmaka: Pharmakokinetische und pharmakodynamische Konsequenzen. Abstract for the AGNP, München, September 2003. *Pharmacopsychiatry* 2003; 36, 213 (abstract 16)
151. Baumann P, van den Heuvel MW, Sitsen JMA, **Eap CB** and Peeters PAM. Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics of mirtazapine in healthy volunteers. Abstract for the ECNP, Prague, September 2003. *European Neuropsychopharmacology*, Vol 13 (Suppl. 4), S241, 2003
152. Jaquenoud Sirot E, **Eap CB**, Baumann P. Can Therapeutic Drug Monitoring and pharmacogenetic tests provide tools in pharmacovigilance? Abstract for the International Society of Pharmacovigilance. Meeting, Marakech, Marocco, October 2003. *Pharmacoepidemiology and Drug Safety*, 12: S234, 2003.
153. Paus E, Jonzier-Perey M, Cochard N, **Eap CB**, Baumann P. Stereoselective LC-MS analysis of mirtazapine and its metabolites in plasma of depressive patients. USGEB. 2003.

154. **Eap CB**, Bender S, Jaquenoud Sirot E, Cucchia G, Baumann P, Chevalier D, Lo-Guidice JM, Suard F, Allorge D, Broly F. Low or ultrarapid CYP1A2 activity leading to overdosage or non-response to clozapine: an analysis of CYP1A2 gene. 23rd Annual symposium 2003 of the Swiss Society of Biological Psychiatry: Schizophrenia: new theories and therapies, Geneva, February 28th 2003. Page O-2 of the abstract book.
155. **Eap CB**, Bender S, Jaquenoud Sirot E, Cucchia G, Baumann P, Chevalier D, Lo-Guidice JM, Suard F, Allorge D, Broly F. Low or ultrarapid CYP1A2 activity leading to overdosage or non-response to clozapine: an analysis of CYP1A2 gene as an example of a pharmacogenetic study. CHUV Research Day January 16, 2003. Abstract NEU-027.
156. Baumann P, **Eap CB**. Intérêt du monitoring des taux plasmatiques de médicaments psychotropes en psychiatrie de l'enfance et de l'adolescence. Symposium on child and adolescent Psychiatry, Berne, Feb. 2003.
157. Baumann P, Nil R, Souche A, Brawand-Amey M, Jonzier-Perey M, **Eap CB**. CYP2C19 dependent pharmacokinetics of (S)- and (R)- citalopram and clinical consequences. Nov. 2002. Monaco. International Journal of Psychiatry in Clinical Practice 6(4): 243, abstract P04, 2002.
158. Baumann P, Zullino D, **Eap CB**. Drug metabolism of antipsychotics and clinical consequences. European Psychiatry, 17 (Suppl. 1) 14S, 2002. 11th Association of European Psychiatrists, Stockholm, May 2002.
159. Baumann P, **Eap CB**. Chiral psychotropic drugs: TDM and pharmacogenetics. AGNP Magdeburg, Germany, 2002. Pharmacopsychiatry 2002;35: VIII
160. Baumann P, Brawand-Amey M, Brocard M, Cochard N, Jaquet S, Jonzier-Perey M, Koeb L, Powell KJ, **Eap CB**. Compliance testing by routine TDM of psychotropic drugs: some observations and methodological issues. AGNP Magdeburg, Germany, 2002. Pharmacopsychiatry 2002;35: IV.
161. Jaquenoud Sirot E, **Eap CB**, Baumann P. TDM and pharmacogenetics as tools in pharmacovigilance: methodological aspects. AGNP Magdeburg, Germany, 2002. Pharmacopsychiatry 2002; 35:VIII.
162. Baumann P, **Eap CB**, Paus E, Zullino D. Industrial and regulatory perspectives on the development of psychotropic drug enantiomers. CINP 2002, Montreal June 2002. Int J Neuropsychopharmacol vol 5 (Suppl. 1), June 2002, p. S50
163. Ciusani E, Zullino D, **Eap CB**, Delacrausaz P, Baumann P. Rapid remission of depression after carbamazepine augmentation of venlafaxine. Abstract book of the 22nd annual symposium of the Swiss society of biological psychiatry, January 2002, Interlaken, Switzerland.
164. Steinacher L, Vandel P, Zullino DF, **Eap CB**, Brawand M, Baumann P. Pharmacokinetic consequences of a carbamazepine augmentation in depressive patients non-responding to citalopram : stereoselective aspects. Abstract book of the 22nd annual symposium of the Swiss society of biological psychiatry, January 2002, Interlaken, Switzerland.
165. Le Bloc'h Y, Woggon B, Weissenrieder H, Zullino D, Brawand-Amey M, **Eap CB**, Baumann P. Therapeutic drug monitoring (TDM) of citalopram in therapy-resistant patients treated with high doses of citalopram: pharmacokinetic aspects. Abstract book of the 22nd annual symposium of the Swiss society of biological psychiatry, January 2002, Interlaken, Switzerland.
166. Steinacher L, Vandel P, Zullino DF, **Eap CB**, Brawand-Amey M, Baumann P. Pharmacokinetic consequences of a carbamazepine augmentation in depressive patients non-responding to citalopram : stereoselective aspects. 22nd Symposium of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Nuremberg, September 2001. Pharmacopsychiatry, 34: 203, 2001.
167. Rostami-Hodlegan A, Foster DJR, Charlier C, Somogyi AA, **Eap CB**, Bochner F, Tucker GT. A meta analysis of the dose-concentration relationship for methadone : a nomogram to assess compliance and metabolic variability. Annual meeting of the British Association of Psychopharmacology (July 2001). J Clin Psychopharmacol, 15(3) A35, 2001
168. **Eap CB** and Baumann P. Pharmacogenomics in drugs of abuse. Annual meeting of the American Association of Clinical chemistry. Chicago, USA, July 2001. Clinical Chemistry 47(6) Suppl.:S15, 2001
169. Baumann P, Paus E, Powell KJ, Brawand-Amey M, **Eap CB**. Therapeutic drug monitoring of chiral psychotropic drugs. 7th World congress of biological Psychiatry, Berlin, July 2001. World J Biol Psychiatry 2001 ; 2:164S
170. **Eap CB** and Baumann P. Pharmacogenetics of methadone : implications for the treatment of opioid dependency. 7th World congress of biological Psychiatry, Berlin, July 2001. World J Biol Psychiatry 2001; 2:1S-384S

171. Fellay J, Marzolini C, Greub G, Buclin T, **Eap CB**, Telenti, A. Predictive power of P-glycoprotein and CYP2D6 polymorphisms for plasma levels of antiretroviral agents. 8th Conference on Retroviruses and opportunistic Infections. Chicago, USA February 2001.
172. Baumann P, Voirol P, Kosel M, Porchet F, Bouras C, **Eap CB**. The fate of psychotropic drugs in the brain. *World Journal of Biological Psychiatry* 2 (Suppl. 1) [S092-01], 164S (2001).
173. De Mendonca Lima CA, **Eap CB**, Baumann P, Gaillard M. Pharmacokinetics of paroxetine in depressed elderly patients : 65 to 79 years old versus more than 80 years old. Abstract book of the symposium on "Depression anxiety spectrum disorders : from neurobiology to novel pharmacological treatments". International academy for biomedical and drug research. September 2000, Milan, Italy.
174. Baumann P, **Eap CB**, Ciusani E, Schröter-Steinacher L, Zullino D. The drug-drug interactions of new antidepressants. Abstracts of the joint meeting of VII World conference on clinical pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics. Florence, Italy, July 2000, *British Journal of Clinical Pharmacology*, CPT2000, 15-20 July-Florence, page 65.
175. **Eap CB** and Baumann P. Pharmacokinetics of methadone and LAAM, and their clinical relevance. 10th Congress of the Association of European Psychiatrists, Prague, October 2000. *European Psychiatry*, Vol 15 (Suppl. 2), p 238s, 2000.
176. **Eap CB**, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P. Pharmacokinetic drug interaction potential of risperidone as assessed by the dextromethorphan, the caffeine and the mephenytoin test. 10th Congress of the Association of European Psychiatrists, Prague, October 2000. *European Psychiatry*, Vol 15 (Suppl. 2), p 394s-395s, 2000.
177. Cuisani E, Zullino DF, **Eap CB**, Delacrausaz P, Baumann P. Rapid remission of depression after carbamazepine augmentation of venlafaxine. 10th Congress of the Association of European Psychiatrists, Prague, October 2000. *European Psychiatry*, Vol 15 (Suppl. 2), p 367s, 2000.
178. Bender S, **Eap CB**, Baumann P, Gastpar M. Sehr hohe CYP1A2-Aktivität und Nonresponse auf Clozapin. *Nervenarzt* 71 (Suppl.1) : S137, DGPPN congress, Aachen, Germany, September 2000.
179. **Eap CB** and Baumann P. Pharmacogenetics of methadone and LAAM : implications for the treatment of opioid dependence. *Therapeutisches Drug Monitoring von Psychopharmaka und psychotropen Substanzen*. AGNP Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. Tübingen, Germany, July 2000.
180. **Eap CB**. Interindividual differences in the metabolism of methadone : Clinical relevance. European opiate addiction treatment association conference, Arezzo (Italie), 3-5 May 2000. *Heroin Addiction and related clinical problems*, Vol 2 (1) Suppl. p 28-29, 2000.
181. **Eap CB**. Genetics and methadone maintenance treatment. American Methadone Treatment Association, San Francisco April 2000. *Heroin Addiction and Related Clinical Problems*, Vol 1, (Suppl. 2) March 2000, p 8.
182. Baumann P, **Eap CB**, Zullino D. Combination treatments in psychiatry : advantages and risks with regard to pharmacokinetic interactions. *World Forum for Mental Health*. 6th World Congress : Innovations in Psychiatry - 2000. London, April 3 - 7, 2000.
183. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW, Kosel M, **Eap CB**, Baumann P. Drug metabolism by cotochrome P-450 in human and rat brain microsomes. 5th ECNP Regional Meeting 2000. St Petersburg, Russia, 15-17 April 2000. *European Neuropsychopharmacology*, Vol 10, (Suppl. 2) 2000, S95-96.
184. Baumann P, **Eap CB**, Zullino D. Interaction determines the choice of medication. 12th congress of the European College of Neuropsychopharmacology, London, UK, September 1999. *European Neuropsychopharmacology*, Vol 9, supplement 5 (1999), S179
185. **Eap CB** and Baumann P. Pharmacokinetic and pharmacogenetics of methadone and other opioids: Clinical relevance. XI World Congress of Psychiatry, Hamburg, Germany, 6-11 August, 1999. *Current Opinion in Psychiatry*, Vol 12, Suppl 1, July 1999, page 50.
186. **Eap CB**, Bourquin M, Martin JL, Livoti S, Baumann P, Déglon JJ. Différence interindividuelle dans le métabolisme de la méthadone: importance clinique. Congrès « Toxicomanie, Hépatite, Sida (THS4) ». Draguignan/Ramatuelle, France, 2-6 Juin 1999.
187. Baumann P, **Eap CB**. Pharmacogenetics: pharmacokinetic and clinical aspects concerning chiral psychotropic drugs. World Federation of Societies of Biological Psychiatry (regional congress). Florence, April 1999.
188. Baumann P, **Eap CB**. New antidepressants and pharmacokinetics. Swiss society for biological psychiatry. Zürich January 1999.

189. Bondolfi G, Huang ML, de Smedt G, **Eap CB**, Zullino D, Baumann P. Fluoxetine addition to risperidone in adult psychotic patients: pharmacokinetic and clinical consequences. ECNP Paris Octobre 98. European Neuropsychology S222.
190. Baumann P, **Eap CB**, Kosel M, Voirol P. Ultrarapid metabolizers: Molecular biology and clinical relevance. AGNP Munich September 1998
191. Déglon JJ, Bourquin M, Martin JL, Livoti S, Baumann P, Powell K, **Eap CB**. Relationship between the number of heroine doses, methadone dosage, methadonemie and levo-methadone blood levels. American methadone treatment association conference, September 26-29, 1998, New York.
192. Kosel M, Voirol P, **Eap CB**, Baumann P. Métabolisme des médicaments dans le cerveau humain: Le rôle du cytochrome P450 et de la monoamine oxidase. Congrès 125 ans Cery, Juin 1998.
193. **Eap CB**, Baumann P. Pharmacogénétique des antidépresseurs, neuroleptiques, et des substances de substitution. Congrès 125 ans Cery, Juin 1998.
194. Fjordside L, Jeppesen U, **Eap CB**, Powell K, Baumann P, Brosen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Annual Meeting, Radisson SAS Falconer Hotel 1988. Nordic Journal of Psychiatry 52 (2):113-114, 1998.
195. Fjordside L, Jeppesen U, **Eap CB**, Powell K, Baumann P, Brosen K. The stereoselective metabolism of fluoxetine in poor and extensive metabolisers of sparteine. 2nd Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin, September 1997. Eur J Clin Pharmacol, 52:A127,1997
196. **Eap CB**, Bertschy G, Finkbeiner T, Gastpar M, Scherbaum N, Baumann P. High interindividual variability of methadone enantiomer blood level to dose ratios challenges restrictive dose-policy regulation. Proceedings of the 7th International Meeting on Clinical Pharmacology in Psychiatry. Badajoz, Spain, October 1997.
197. Baumann P. and **Eap CB**. Pharmacogenetics of recent psychotropic drugs and clinical relevance. 20 th symposium of AGNP, Nuremberg, October 1997. Pharmacopsychiatry, 30:152,1997.
198. Baumann P. and **Eap CB**. Role of cytochrome P-450 in drug abuse. 6th World congress of Biological Psychiatry, Nice, June 1997. Biol. Psychiatry,42:129S, 1997.
199. **Eap CB**, Bertschy G, Finkbeiner T, Gastpar M, Scherbaum N, Baumann P. High interindividual variability of methadone enantiomer blood level to dose ratios challenges restrictive dose-policy regulation. 6th World congress of Biological Psychiatry, Nice, June 1997. Biol. Psychiatry 42:158S,1997.
200. **Eap CB**, de Mendonça Lima CA, Powell K, Baumann P. Moderate influence of the debrisoquine genotype on the steady-state concentrations of the enantiomers of mianserin. 6th World congress of Biological Psychiatry, Nice, June 1997. Biol. Psychiatry, 1997; 42:44S.
201. **Eap CB**, Bertschy G, Finkbeiner T, Gastpar M, Scherbaum N, Baumann P. High interindividual variability of methadone enantiomer blood level to dose ratios challenges restrictive dose-policy regulation. Proceedings of the annual meeting of the Swiss Society of Biological Psychiatry, Fribourg, Jan 1997.
202. **Eap CB**, de Mendonça L, Woggon B, Macciardi F, Powell K, Baumann P. Moderate influence of the debrisoquine genotype on the steady-state concentrations of the enantiomers of mianserin. Proceedings of the annual meeting of the Swiss Society of Biological Psychiatry, Fribourg, Jan 1997.
203. Baumann P, Bondolfi G, Bertschy G, **Eap CB**, Vandel S. Association of SSRI's with tricyclic antidepressants, SSRI's or Li: clinical, pharmacokinetic and pharmacogenetic aspects. European Neuropsychopharmacology, Vol 6, p 217, 1996 (CINP, Melbourne, June 1996).
204. Baumann P, **Eap CB**, Macciardi F, Bender S. Pharmakogenetik von chiralen psychotropen Pharmaka am Beispiel von Trimipramin. Fortschr. Neurol. Psychiatr 64SH2, p 165, 1996 (Drei Länder Symposium für biologische Psychiatrie, Würzburg, October 1996).
205. **Eap CB**, Koeb L, Amey M, Baumann P. Concentrations of the enantiomers of trimipramine and its metabolites in CYP2D6 and CYP2C19 phenotyped patients. European Neuropsychopharmacology. vol 6, p 42, 1996 (CINP, Melbourne, June 1996).
206. Baumann P, **Eap CB**, Finkbeiner T, Lodemann E, Bertschy G. New aspects in the pharmacokinetics and metabolism of methadone. *Eur. Psychiatry* 11:170s-171s, 1996 (8th Congress of Association of European Psychiatrists, London, 7-12 July 1996).
207. **Eap CB**, Guentert T, Schäublin-Loidl M, Stabl M, Koeb L, Powell K, Baumann P. The role of CYP2D6 and CYP2C19 in the stereoselective metabolism of thioridazine in patients. *Ther Drug Monit* 17:Abstr.150 p 420, 1995 (TDM, Vienna, Sep 1996).

208. Baumann P, **Eap CB**, Rochat B, Bondolfi G, Bertschy G. Clinical relevance of the genetic polymorphism of cytochrome P-450 isozymes in the pharmacotherapy of psychiatric patients. *Pharmacopsychiat* 28: 164 (1995). 19th Symposium AGNP, Nuremberg, 1995.
209. Finkbeiner T, **Eap CB**, Leifert K, Scherbaum N, Baumann P, Gastpar M. Methadone plasma levels after replacement of L- methadone with racemic methadone. *Pharmacopsychiat* 28: 176 (1995). 19th Symposium AGNP, Nuremberg, 1995.
210. Baumann P, **Eap CB**. Plasmaspiegelbestimmungen von chiralen Psychopharmaka. *Psychopharmakotherapie*, Heft 1: 29-30 (1995).
211. **Eap CB**, Powell K, Taeschner W, Baumann P. Plasma levels of the enantiomers of mianserin in CYP2D6-genotyped patients. *Eur. Neuropsychopharmacol.* 4: 304, 1994.
212. Baumann P, **Eap CB**, and Bertschy G. Evaluation biologischer Therapien psychischer Erkrankungen. *Neuropsychiatrie* 8: 27-28, 1994.
213. Baumann P, **Eap CB**, Koeb L, Kasas A, Blajev R, Holsboer E, Bajetta G, Zöchling R, Mascetti R, Schäublin-Loidl M. Pharmacogenetic investigations in moclobemide (MOCL) + thioridazine (THD) vs MOCL + placebo-treated depressive patients. *Neuropsychopharmacology* 10:75S, 1994.
214. Bertschy G, **Eap CB**, Baumann P. Methadone plasma levels after fluvoxamine or fluoxetine addition. *Neuropsychopharmacology* 10: 128S, 1994.
215. **Eap CB**, Koeb L, Baumann P. Chromatographic separation of the enantiomers of mianserin and its metabolites. Fourth International Symposium on Chiral Discrimination. Montreal 1993. Abstract 74, p 61.
216. Seifritz E, Holsboer-Trachsler E, Hemmeter U, **Eap CB**, and Baumann P. Increased trimipramine plasma levels during fluvoxamine comedication. *Pharmacopsychiat.* 26: 195, 1993. 18th Symposium of AGNP, Neuremberg
217. Baumann P, **Eap CB**, and Bertschy G. Pharmacogenetic investigations of phenotyped psychiatric patients. 9th World Congress of Psychiatry, Rio de Janeiro, June 6th - 12th, 1993, Brazil. *Abstract* 117, 1993.
218. **Eap CB**, Rochat B, and Baumann P. Chromatographic separation of chiral psychotropic drugs: Examples of trimipramine and citalopram. Book of abstracts 3rd International Symposium on Chiral Discrimination. Tübingen, Germany. October 5-8, 1992, p. 180 abstract 153.
219. Baumann P and **Eap CB**. Klinische Relevanz pharmakogenetischer Phänotypisierungen. *Fortschr. Neurol. Psychiat.* 60: 20, 1992.
220. Baumann P and **Eap CB**. Clinical relevance of phenotyping groups of patients for psychotropic drug trials. *Clin. Neuropharmacol.* 15 (Suppl.1): 86A-87A, 1992.
221. Souche A, **Eap CB**, Nil R, Reymond P, Reymond MJ, Lambert S, Montaldi S, Amey M, Jonzier-Perey M, and Baumann P. Citalopram with addition of lithium or placebo (double blind) in the treatment of therapy-resistant depressive patients: methodology and biological investigation. *Biological Psychiatry* 29: 382S, 1991.
222. **Eap CB**, Laurian S, Reymond P, Souche A, Koeb L, Cuendet C, Jonzier-Perey M, and Baumann P. Influence of quinidine on the pharmacokinetics of trimipramine and on the EEG measured in two healthy volunteers: a pilot study. *Biological Psychiatry* 29: 360S, 1991.
223. Baumann P. and **Eap CB**. Plasma monitoring of antidepressants: clinical relevance of the pharmacogenetics of metabolism and of alpha1-acid glycoprotein binding. *Biological Psychiatry* 29: 116S, 1991.
224. **Eap CB**, Koeb L, Souche A, and Baumann P. Light-induced racemization of the diastereoisomeric pairs of thioridazine 5-sulfoxide : origin of artefacts in the TDM of thioridazine. *Quimica Clinica* 9: 327, 1990.
225. **Eap CB**, Souche A, Koeb L, Jonzier-Perey M, Cuendet C, and Baumann P. Influence of quinidine on the metabolism of trimipramine in two healthy volunteers after an oral dose of 75 mg trimipramine: preliminary results. In: Ingelman-Sundberg M, Gustafsson JA, Orrenius S (Eds) Drug Metabolizing Enzymes: Genetics, Regulation and Toxicology. Proceedings of the VIIIth Internat. Symp. on Microsomes and Drug Oxidations, Stockholm, June. *Abstract* 196, 1990.
226. **Eap CB**, Koeb L, Souche A, and Baumann P. Light-induced racemization of the diastereoisomeric pairs of thioridazine 5-sulfoxide: higher concentrations of the eluting stereoisomeric pairs are measured in plasma and urine of thioridazine-treated patients following light-protected extraction steps. European Society of Biochemical Pharmacology. Abstract, twelfth European Workshop on Drug Metabolism. Base, Septembre 16-21, 1990.
227. **Eap CB**, Cuendet C, and Baumann P. Alpha 1-Acid glycoprotein: an interesting for studying pharmacogenetic aspects of drug-protein interactions. Association Suisse de Psychiatrie Biologique. Abstract. 10, 1989.

228. Dente L, **Eap CB**, Baumann P, and Tomei L. Expression of human alpha1-acid glycoprotein in transgenic mice: characterization of genetic variants. Abstract presented at the 1989 meeting on Regulation of Liver Gene Expression, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
229. **Eap CB**, Baumann P, and Moretta A. Synthesis of alpha1-acid glycoprotein by human T lymphocytes. *Experientia* 45: A52, 1989.
230. **Eap CB**, Cuendet C, and Baumann P. In vitro binding studies with amitriptyline to the isolated S- and F-forms of variants of human alpha1-acid glycoprotein. *Therapie* 43: 162, 1988.
231. **Eap CB**, Cuendet C, and Baumann P. Drug binding studies with the S- and F-forms of human alpha1-acid glycoprotein variants by multicompartamental equilibrium dialysis. *Experientia* 44: A15, 1988.
232. Baumann P and **Eap CB**. Das saure Alpha1 Glykoprotein: ein Modell zum Studium pharmakogenetischer Aspekte von Wechselwirkungen zwischen Eiweissen und psychotropen Pharmaka? *Fortschritte der Neurologie Psychiatrie* 56: 16, 1988
233. **Eap CB**, Cuendet C, and Baumann P. Aspect pharmacogénétique de la liaison de l'amitriptyline à l'alpha1 glycoprotéine acide. *Encephale* XIII: 142-143, 1987.
234. **Eap CB**, Cuendet C, and Baumann P. In vitro binding studies with amitriptyline to the isolated S- and F-forms of variants of human alpha1-acid glycoprotein. *Experientia* 43: 702, 1987.
235. **Eap CB**, Cuendet C, and Baumann P. Analytical and preparative isoelectric focusing (IEF) of the F- and S -forms of alpha1-acid glycoprotein (AAG) variants for binding studies. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 334: R54, 1986.